US20210368788A1 - Methods for using antimicrobial compositions - Google Patents
Methods for using antimicrobial compositions Download PDFInfo
- Publication number
- US20210368788A1 US20210368788A1 US17/402,535 US202117402535A US2021368788A1 US 20210368788 A1 US20210368788 A1 US 20210368788A1 US 202117402535 A US202117402535 A US 202117402535A US 2021368788 A1 US2021368788 A1 US 2021368788A1
- Authority
- US
- United States
- Prior art keywords
- composition
- acid
- solute
- biofilm
- sinus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 153
- 238000000034 method Methods 0.000 title claims description 43
- 230000000845 anti-microbial effect Effects 0.000 title description 5
- 241000894006 Bacteria Species 0.000 claims abstract description 36
- 210000004081 cilia Anatomy 0.000 claims abstract description 26
- 210000000959 ear middle Anatomy 0.000 claims abstract description 15
- 210000003027 ear inner Anatomy 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims description 28
- 239000002253 acid Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 229940088598 enzyme Drugs 0.000 claims description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000003945 anionic surfactant Substances 0.000 claims description 14
- 102000016943 Muramidase Human genes 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 13
- 229960000274 lysozyme Drugs 0.000 claims description 13
- 108010014251 Muramidase Proteins 0.000 claims description 12
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 12
- 239000004325 lysozyme Substances 0.000 claims description 12
- 235000010335 lysozyme Nutrition 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000002243 precursor Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 150000007524 organic acids Chemical class 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 11
- 238000001228 spectrum Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 19
- 239000011159 matrix material Substances 0.000 description 17
- 239000003352 sequestering agent Substances 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 15
- 239000002585 base Substances 0.000 description 14
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 150000007513 acids Chemical class 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 230000021148 sequestering of metal ion Effects 0.000 description 12
- 239000004094 surface-active agent Substances 0.000 description 12
- -1 organic acids and Chemical class 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 239000004599 antimicrobial Substances 0.000 description 8
- 230000035559 beat frequency Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000007943 implant Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000010009 beating Methods 0.000 description 6
- 230000002262 irrigation Effects 0.000 description 6
- 238000003973 irrigation Methods 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 206010011878 Deafness Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 231100000888 hearing loss Toxicity 0.000 description 5
- 230000010370 hearing loss Effects 0.000 description 5
- 208000016354 hearing loss disease Diseases 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229910021645 metal ion Inorganic materials 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 210000003454 tympanic membrane Anatomy 0.000 description 5
- 241000233866 Fungi Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000004626 scanning electron microscopy Methods 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010033078 Otitis media Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010033109 Ototoxicity Diseases 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- UJMDYLWCYJJYMO-UHFFFAOYSA-N benzene-1,2,3-tricarboxylic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1C(O)=O UJMDYLWCYJJYMO-UHFFFAOYSA-N 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000024035 chronic otitis media Diseases 0.000 description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 210000003477 cochlea Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000012188 high-throughput screening assay Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004086 maxillary sinus Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 231100000262 ototoxicity Toxicity 0.000 description 2
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- CYIDZMCFTVVTJO-UHFFFAOYSA-N pyromellitic acid Chemical compound OC(=O)C1=CC(C(O)=O)=C(C(O)=O)C=C1C(O)=O CYIDZMCFTVVTJO-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UTNSTTZHNMPBEE-UHFFFAOYSA-N 2-chloro-2-hydroxy-2-phenylacetic acid Chemical compound OC(=O)C(O)(Cl)C1=CC=CC=C1 UTNSTTZHNMPBEE-UHFFFAOYSA-N 0.000 description 1
- GPICKHDXBPTBLD-UHFFFAOYSA-N 2-methylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(C)(CC(O)=O)C(O)=O GPICKHDXBPTBLD-UHFFFAOYSA-N 0.000 description 1
- HABHUTWTLGRDDU-UHFFFAOYSA-N 2-oxopimelic acid Chemical compound OC(=O)CCCCC(=O)C(O)=O HABHUTWTLGRDDU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700114 Chinchillidae Species 0.000 description 1
- 206010008642 Cholesteatoma Diseases 0.000 description 1
- XFTRTWQBIOMVPK-YFKPBYRVSA-N Citramalic acid Natural products OC(=O)[C@](O)(C)CC(O)=O XFTRTWQBIOMVPK-YFKPBYRVSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000005325 alkali earth metal hydroxides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001963 alkali metal nitrate Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- NHDLVKOYPQPGNT-UHFFFAOYSA-N benzene-1,2,3,5-tetracarboxylic acid Chemical compound OC(=O)C1=CC(C(O)=O)=C(C(O)=O)C(C(O)=O)=C1 NHDLVKOYPQPGNT-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- XFTRTWQBIOMVPK-UHFFFAOYSA-N citramalic acid Chemical compound OC(=O)C(O)(C)CC(O)=O XFTRTWQBIOMVPK-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 150000007520 diprotic acids Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002388 eustachian tube Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000001457 metallic cations Chemical class 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000007518 monoprotic acids Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 208000005923 otitis media with effusion Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- WDFRNBJHDMUMBL-OICFXQLMSA-M sodium;(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 WDFRNBJHDMUMBL-OICFXQLMSA-M 0.000 description 1
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 1
- 229960001262 tramazoline Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 150000007521 triprotic acids Chemical class 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/50—Isolated enzymes; Isolated proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
Definitions
- Microbes are found virtually everywhere, often in high concentrations, and are responsible for a significant amount of disease and infection. Eliminating these microorganisms from targeted tissues is often desirable and sometimes critically important.
- Bacteria present special challenges because they can exist in a number of forms, including planktonic, spore and biofilm, and their various self-preservation mechanisms make treating and/or eradicating them extremely difficult.
- the bacteria in biofilms or spores are down-regulated (sessile), making them resistant to attack by a large group of antibiotics and antimicrobials that are effective only during the active parts of a bacterium's lifecycle, e.g., cell division.
- microbes such as bacteria or fungi interact with and adhere to surfaces, forming colonies which facilitate continued growth.
- the microbes produce exopoly-saccharide (EPS) and/or extracellularpolysaccharide (ECPS) macromolecules that keep them attached to a surface and form a protective barrier effective against many forms of attack.
- EPS exopoly-saccharide
- ECPS extracellularpolysaccharide
- the small diameter of flow channels in the EPS/ECPS macromolecular matrix which restricts the size of molecules that can reach the underlying microbes, and consumption of biocides through interactions with portions of the EPS/ECPS macromolecular matrix and microbe secretions and waste products contained therein probably play roles in the protective barrier function.
- microbes in a biofilm state are very difficult to treat.
- the types of biocides and antimicrobials effective in treating microbes in this form often are strongly acidic or caustic, and often oxidizing due to the presence of halogen atoms, oxygen atoms, or both. Large dosages of such chemicals must be allowed to contact the biofilm for extended amounts of time to be effective, which makes them impractical for many applications.
- compositions intended for use in connection with compromised animal/human tissue which solvate a biofilm matrix so that it can be rinsed or otherwise removed from infected tissue have been described in, e.g., U.S. Pat. Nos. 7,976,873, 7,976,875, 7,993,675, and 7,959,943.
- Compositions based on similar components but intended for other uses have been described in U.S. Pat. Nos. 8,940,792 and 9,314,017 and U.S. Pat. Publ. Nos. 2010/0086576, 2014/0242188, and 2016/0073628.
- compositions such as those described in the preceding paragraph when applied to ciliated tissue such as exist in the sinus cavities and inner ear, tend to result in deciliation, i.e., the loss in functionality and/or removal of cilia, which are the relatively thick protruding organelles found in and projecting from the bod of eukaryotic cells.
- Sinus cavity cilia facilitate clearance of the sinuses, while those in the ear act as sound receptors.
- compositions described in the documents listed in the preceding paragraph all call for at least 0.2% (w/w) surfactant, and many require or prefer low pH and very high effective solute concentrations, i.e., osmolarities.
- compositions intended for use in treating portions of the ear inward of the tympanic membrane (or treating a sinus cavity that is connected to the inner ear) cannot be permitted to result in deciliation because inner ear cilia do not regrow, resulting in irreparable hearing loss.
- compositions that can effectively treat microbes present in cilia-containing areas such as the sinus cavities and middle/inner ear, particularly microbes in a biofilm form, without resulting in unacceptable levels of deciliation.
- a composition that can accomplish the foregoing while also causing or facilitating detachment of biofilms from affected tissue is particularly desirable.
- Such an antimicrobial composition that can be provided in a variety of viscosities and introduced to the targeted area via more than one delivery route is particularly desirable.
- composition that is sufficiently biocompatible so as to not require removal via irrigation using, for example, a saline rinse.
- the present invention is directed to compositions that can be used to treat microbes including but not limited to bacteria, including those in biofilm form.
- the term “treat” includes killing, inactivating and/or removal.
- a composition according to the present invention is effective against a wide spectrum of gram positive and gram negative bacteria and exhibits lethality toward other microbes such as viruses, fungi, molds, and yeasts.
- this composition can effectively kill microbes present in cilia-containing areas such as the sinus cavities and middle/inner ear, even microbes in a biofilm form, while resulting in no, or very minimal amounts of, deciliation.
- a targeted treatment area includes a biofilm
- the composition often can detach and assist in removing the biofilm from affected tissue.
- the composition typically is provided as a liquid having a viscosity similar to that of water, but can be thickened to provide a variety of forms with a range of viscosities. It also can be delivered via techniques employing a variety of presently available equipment.
- compositions are biocompatible, while many embodiments are ciliacompatible.
- the composition has a near-neutral pH, typically from 6 to 8, and includes a moderate amount of osmotically active solutes, often having an effective solute concentration of no more than 400 mOsm/L, commonly no more than 250 mOsm/L and more commonly no more than 200 mOsm/L.
- Embodiments intended for use in the sinus cavities can include no more than 1.0, 0.8, 0.7 or 0.5% (w/v) of one or more anionic surfactants, while other embodiments intended for use in the middle or inner ear can include no added surfactant(s).
- the composition includes at least 2% (w/v) of one or more non-aqueous liquids, with the upper limit determined in large part by the intended end use of the composition.
- the composition also includes at least 0.005% (w/v) of one or more enzymes which are active at 6 ⁇ pH ⁇ 8 so as to facilitate microbial cell wall rupture by catalyzing and/or easing the breaking of chemical bonds present in or between molecules in those cell walls.
- enzymes vary so widely in terms of chemical structure and targeted utility, the upper limit often is based on the amount of a particular enzyme, if any, that results in a level of ciliotoxicity deemed to be unacceptable for a particular end use.
- the composition is effective at interrupting or breaking ionic crosslinks in the macromolecular matrix of a biofilm, which facilitates passage of the solutes, surfactant (if present) and enzyme through the matrix to the microbes (e.g., bacteria) entrained therein and/or protected thereby.
- the composition thus bypasses and/or disables the biofilm defenses, allowing previously protected microbes to be accessed and killed, typically by processes that include inducing membrane leakage in bacteria, leading to cell lysis.
- compositions can be non-flowing if intended to be left in place or can be a liquid if intended to irrigate or otherwise flow over or around a treatment area.
- Embodiments of the composition can be used to treat chronic otitis media, cholesteatoma and other bacterial ear conditions, as well as chronic rhinosinusitis and other bacterial sinus conditions.
- a flowable form of the composition is introduced peri- or post-surgery performed on an affected area.
- a composition can be introduced into the middle ear via a tympanostomy tube immediately or soon after its insertion or, if deemed necessary desirable, during a post-surgical follow-up evaluation.
- pH values of a liquid are those which can be obtained from any of a variety of potentiometric techniques employing a properly calibrated electrode, and effective solute concentrations preferably are determined by latent heat of fusion calculations from a properly calibrated DSC unit-produced scan acquired over a temperature range that includes the melting temperature of a given liquid composition.
- any numerical limitation used herein includes an appropriate degree of uncertainty based on the number of significant places used with that particular numerical limitation. For example, “up to 5.0” can be read as setting a lower absolute ceiling than “up to 5.”
- FIG. 1 is a perspective, schematic view of a disassembled simplified multiwell array, of the type employed in a minimum biofilm eradication concentration (MBEC) high throughput screening assay.
- MBEC biofilm eradication concentration
- FIG. 2 is a top view of an 8 ⁇ 12 multiwell array employed in the testing of treating compositions of the present invention.
- FIG. 3 is a top view of a challenge plate matrix employed in the testing of treating compositions of the present invention.
- FIGS. 4 and 5 depict Air-Liquid Interface (ALI) model ciliotoxicity testing results for a sinus treatment composition, with active cilia area plotted against time in FIG. 4 and cilia beat frequency plotted against time in FIG. 5 .
- ALI Air-Liquid Interface
- FIG. 6 depicts averaged baseline hearing threshold data for eight guinea pigs.
- FIGS. 7 and 8 depict averaged threshold shifts in hearing for eight guinea pigs, with FIG. 7 being based on data collected 7 days after liquid insertion and FIG. 8 being based on data collected 28 days after liquid insertion.
- compositions such as those summarily described in the preceding section can be used to break down, remove and/or disrupt biofilms including, advantageously, bacterial biofilms located in the middle or inner ear or the sinus cavities of an animal, particularly a mammal.
- the compositions are biocompatible and safe to use in and around the delicate tissues and structures of those areas because they are free of constituent materials which might harm such tissues or structures or unduly compromise long-term hearing.
- Embodiments of the composition have a sufficiently low viscosity to enable delivery using techniques such as spray application, lavage, misting, mopping, wicking and dripping. These and other embodiments of the composition also can be easily removed from the treatment site by subsequent flushing, rinsing, and draining, although many such embodiments are sufficiently biocompatible to allow for absorption.
- a metal ion sequestering agent in the composition might complex or otherwise bond with metal ions which crosslink, bridge or otherwise assist in binding together polymer chains in the EPS/ECPS matrix of a biofilm.
- Other components of the composition then might surround the unbound polymer chains or fragments, breaking down the matrix, solvating the uncrosslinked polymer chains or fragments, and bringing them into solution or suspension so that they can be flushed or otherwise removed from the treatment area using, for example, additional amounts of the solvating system or a separate rinsing agent.
- the composition includes solvent and solute components.
- the solvent component of the composition includes water and at least one non-aqueous liquid.
- Water has a high solute holding capability, good wetting properties, excellent biocompatibility, environmental friendliness, and low cost. Essentially any source of water can be used, although those that are relatively free of bacteria without advance treatment are preferred. The water need not be distilled, deionized, or the like, although such treatments certainly are not excluded, particularly where the water employed might include undesirable solutes which might interfere with the intended purpose of the composition. To enhance solubility of one or more of the other components of the composition, the water can be heated.
- the one or more non-aqueous liquids typically has/have a ⁇ p value no higher than that of water, where ⁇ p is the dipolar intermolecular force (polarity) Hansen Solubility Parameter (HSP), a common method for predicting whether one material will dissolve in another to form a solution; the HSP values for most commonly used solvents are well documented.
- polarity dipolar intermolecular force
- HSP Hansen Solubility Parameter
- HSPs dispersion, dipole-dipole (polarity) interactions, and hydrogen bonding.
- These parameters are generally treated as coordinates in three dimensions, with HSP characterizations being visualized using a spherical representation: the 3D coordinates are at the center of the sphere with the radius of the sphere (R 0 or “interaction radius”) indicating the maximum difference in affinity tolerable for a “good” interaction with a solvent or solute.
- R 0 or “interaction radius” the maximum difference in affinity tolerable for a “good” interaction with a solvent or solute.
- acceptable solvents lie within the interaction radius, while unacceptable ones lie outside it.
- ⁇ d is the energy from dispersion forces between the molecules
- ⁇ p is the energy from dipole-dipole intermolecular forces
- ⁇ h is the energy from hydrogen bonds between molecules.
- RED Relative Energy Difference
- the dipole-dipole interaction Hansen solubility parameter for a particular solution or mixture of solvents can be calculated according to the following formula:
- ⁇ di is the energy from dipolar intermolecular force for solvent i
- x di is the percentage of solvent i in the solvent portion of the composition
- n is the total number of solvent components.
- the ⁇ p value for a given solvent or combination of solvents is determined at room temperature (because solubility typically increases with increasing temperature, meaning that the dissolution rate of the macromolecular matrix and the bacterial cell wall proteins will increase, the efficacy of the inventive composition is expected to increase at higher temperatures) and pH values are those which can be obtained from any of a variety of potentiometric techniques employing a properly calibrated electrode.
- the solvent component of the composition includes at least one non-aqueous liquid, typically one with a ⁇ p value no higher than that of water ( ⁇ p ⁇ 16.0 MPa 1/2 ).
- exemplary composition intended for use in a sinus application can employ 5-20% (w/v) dimethyl sulfoxide (DMSO) with an overall ⁇ p ⁇ 16.0 MPa 1/2
- exemplary compositions intended for use in an otic application can employ 5-15% (w/v) ethanol with an overall ⁇ p 15.4 MPa 1/2 .
- preference can be given to those organic compounds which are, or can be made to be, highly soluble in water and to those which are ciliacompatible. Additionally, preference can be given to any organic liquid that has been deemed to be safe and “inactive” (by regulatory bodies) at intended usage levels.
- the composition includes at least 2% (w/v) of one or more non-aqueous (organic) liquids, with the upper limit determined in large part by the intended end use of the composition, i.e., the upper limit for sinus applications probably is higher than that for otic applications.
- the lower limit can be 2.1, 2.2, 2.3, 2.4 or even 2.5%, with all of the foregoing being presented in w/v format.
- Exemplary ranges include 2.25-15% (sinus) or 2.0-10% (otic), with typical ranges being 2.5-13% (sinus) and 2.1-9% (otic) and preferred ranges being 2.5-12.5% (sinus) and 2.2-8% (otic), again with all of the forgoing being presented in w/v format.
- the composition also includes as a primary component a solute component which can contain as few as two sub-components: the dissociation product(s) of at least one metal ion sequestering agent and at least one effective enzyme.
- a solute component which can contain as few as two sub-components: the dissociation product(s) of at least one metal ion sequestering agent and at least one effective enzyme.
- anionic surfactant also can be included.
- the dissociation product(s) of one or more salts also can be included to increase effective solute concentration.
- Each of the foregoing ingredients generally is considered to be biocompatible.
- the metal ion sequestering agent can be an acid or base capable of complexing or otherwise reacting with one or more metal ions in the EPS/ECPS matrix of a biofilm.
- Metal ions of particular interest due to their likely involvement in the targeted biofilms, include sodium, calcium and iron.
- the metal ion sequestering agent desirably is water soluble, nontoxic and not prone to aggravate long-term hearing loss.
- Acids generally are preferred over bases, although either type of sequestering agent can be used. Preference can be given to those metal ion sequestering agents which are biocompatible. Alternatively or additionally, preference can be given to those metal ion sequestering agents which can act to chelate the metallic cations ionic involved in crosslinking the macromolecular matrix of a biofilm.
- the metal ion sequestering agent preferably is not considered to be an oxidizer, particularly if it is an acid. Additionally, strong preference can be given to those acids and bases that have been deemed to be safe or “inactive” (by regulatory bodies) at intended usage levels
- Acidity is achieved by adding to water (or vice versa) one or more acids, specifically strong (mineral) acids such as HCl, H 2 SO 4 , H 3 PO 4 , HNO 3 , H 3 BO 3 , and the like or, preferably, weak acids, particularly organic acids and, preferably, organic polyacids.
- acids specifically strong (mineral) acids such as HCl, H 2 SO 4 , H 3 PO 4 , HNO 3 , H 3 BO 3 , and the like or, preferably, weak acids, particularly organic acids and, preferably, organic polyacids.
- organic acids include monoprotic acids such as formic acid, acetic acid and substituted variants, propanoic acid and substituted variants (e.g., lactic acid, pyruvic acid, and the like), any of a variety of benzoic acids (e.g., mandelic acid, chloromandelic acid, salicylic acid, and the like), glucuronic acid, and the like; diprotic acids such as oxalic acid and substituted variants (including oxamic acid), butanedioic acid and substituted variants (e.g., malic acid, aspartic acid, tartaric acid, citramalic acid, and the like), pentanedioic acid and substituted variants (e.g., glutamic acid, 2-ketoglutaric acid, and the like), hexanedioic acid and substituted variants (e.g., mucic acid), butenedioic acid (both cis and trans isomers), iminodiacetic acid
- one or more of the carboxyl protons can be replaced by cationic atoms or groups (e.g., alkali metal ions), which can be the same or different.
- Preferred acids include mono-, di- or tri-protic citric acid, acetic acid, octanoic acid and glutamic acid.
- Basicity is achieved by adding to water (or vice versa) one or more bases such as, but not limited to, alkali metal salts of weak acids including acetates, fulmates, lactates, phosphates, and glutamates; alkali metal nitrates; alkali metal hydroxides, in particular NaOH and KOH; alkali earth metal hydroxides, in particular Mg(OH) 2 ; alkali metal borates; NH3; and alkali metal hypochlorites (e.g., NaClO) and bicarbonates (e.g., NaHCO 3 ).
- bases such as, but not limited to, alkali metal salts of weak acids including acetates, fulmates, lactates, phosphates, and glutamates; alkali metal nitrates; alkali metal hydroxides, in particular NaOH and KOH; alkali earth metal hydroxides, in particular Mg(OH) 2 ; alkali metal borates; NH3; and
- the concentration of metal ion sequestering agent added to water, or vice versa is relatively unimportant because of the targeted effective solute concentration and hydronium ion concentration, i.e., 6 ⁇ pH ⁇ 8.
- concentration of metal ion sequestering agent added to water is relatively unimportant because of the targeted effective solute concentration and hydronium ion concentration, i.e., 6 ⁇ pH ⁇ 8.
- use of a strong acid or base militates against addition of large amounts of that acid/base.
- the relatively moderate effective solute concentration limits (discussed below) argue against significant amounts of buffer precursor.
- use of a very weak acid or base permits addition of a much larger amount of the acid/base and/or a much reduced amount of a buffer precursor.
- the amount(s) of acid(s) or base(s) necessary to reach a given t value will, of course, depend on the strength of the particular acid(s) or base(s) used. Because even small amounts of those compounds considered to be weak acids or bases will adjust a composition's pH, respectively, below or above the aforementioned t values, the solute component almost always includes sufficient amounts of a buffer precursor (discussed below) so as to provide a composition having a desired t.
- each of the documents set forth in the preceding paragraph requires moderate-to-high levels of one or more surfactants.
- the compositions of the present invention are intended to be used in the presence of cilia and because many types of surfactant are known to be ciliotoxic, inclusion of surfactants is contraindicated.
- an efficacy-enhancing option from the aforementioned prior teachings is not available (or much less available) in compositions of the present invention
- the amount of anionic surfactant to be included in embodiments intended for use in sinus-related applications generally is less than 1.0%, commonly less than 0.75%, typically less than 0.5%, preferably less than 0.4%, more preferably less than 0.35%, and most preferably less than 0.3%, all presented in w/v format.
- the total amount present generally is from 0.02 to 0.67%, commonly from 0.03 to 0.55%, typically from 0.04 to 0.42%, preferably from 0.05 to 0.39%, even more preferably from 0.06 to 0.36%, and still more preferably from 0.08 to 0.33%, all again w/v.
- anionic surfactants include, but are not limited to, sodium chenodeoxycholate, N-lauroylsarcosine sodium salt, lithium dodecyl sulfate, 1-octanesulfonic acid sodium salt, sodium cholate hydrate, sodium deoxycholate, sodium dodecyl sulfate, sodium glycodeoxycholate, sodium lauryl sulfate, and the alkyl phosphates set forth in U.S. Pat. No. 6,610,314.
- the enzyme sub-component of the solute component can be any one or more which is/are capable of facilitating microbial cell wall rupture by catalyzing and/or easing the breaking of chemical bonds present in or between molecules in those cell walls.
- One category believed to be particularly effective is glycosidase, particularly the species lysozyme. Testing to date has shown that lysozyme exhibits some efficacy at amounts as low as 80 ppm, i.e., 0.08 g lysozyme per kg of composition.
- Commonly employed amounts of enzyme(s) are at least 100 ppm, at least 125 ppm, and at least 150 ppm.
- Exemplary ranges include 85 to 500 ppm, 90 to 450 ppm, 95 to 400 ppm, 100 to 350 ppm, 105 to 300 ppm, 110 to 275 ppm, 115 to 250 ppm, 120 to 225 ppm, 125 to 200 ppm, 130 to 190 ppm, 135 to 185 ppm, and 140 to 180 ppm.
- Composition efficacy generally increases with the presence of at least moderate effective solute concentrations, which generally increases in proportion with the amounts of solute subcomponents employed.
- solute subcomponents generally increases in proportion with the amounts of solute subcomponents employed.
- solute concentration tonicity
- other water soluble compounds can be included in the solute component. Such compounds, upon dissociation, increase the effective amount of solutes in the composition without greatly impacting the molar concentration of hydronium and hydroxyl ions.
- Effective solute concentration of a composition can be increased by adding large amounts of ionic compounds, particularly electrolytes; see, e.g., U.S. Pat. No. 7,090,882.
- any compound that at least partially dissociates in water and/or the organic liquid(s) employed in the solvent component can be used to achieve this effect, with exemplary compounds including, but not being limited to, phosphates, acetates and any material deemed to be an “inactive ingredient” in injections, gels, creams, lotions, and/or ointments by governmental regulatory bodies.
- a preferred method of increasing composition tonicity is employing a buffer precursor as a subcomponent of the solute component.
- the solute component includes one or more acids
- one or more salts of those or other acids can be employed as solute subcomponent(s) which, in addition to increasing tonicity of the composition, provides a pH buffer to it.
- an excess e.g., 2x-8x
- an excess e.g., 2x-8x
- the identity of the countercation of the acid salt (or counteranion of the base salt) is not particularly important.
- salt of a polyacid is used as a buffer precursor
- all or fewer than all of the carboxyl hydrogen atoms can be replaced; for example, mono-, di- and trisodium citrate all constitute potentially useful buffer precursors but the latter provides a greater theoretical buffering capacity than either of the other two. (Again, the same is true for salts of a polybase, mutatis mutandis.)
- the tonicity of the composition is moderately high, with an effective solute concentration of from 100 to 300 mOsm/L being common and 200 ⁇ 10 mOsm/L being typical.
- Embodiments of the composition can exhibit minimum solute concentrations of 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175 or 180 mOsm/L and maximum solute concentrations of 275, 260, 250, 245, 240, 235, 230, 225, 220, 215, 210, 205, 200, 195, 190 or 185 mOsm/L.
- Ranges based on each of the minimums and each of the maximums are envisioned, with some exemplary options including, but not being limited to, 110 to 275, 125 to 250, 150 to 250, 160 to 240, 160 to 225, 175 to 250, 170 to 240, 170 to 230, 180 to 240, 180 to 235, and 180 to 220 mOsm/L.
- any of a variety of additives and adjuvants can be included in the solute component to make a composition more amenable for use in a particular end-use application with negatively affecting its efficacy in a substantial manner.
- additives and adjuvants include, but are not limited to, fragrances, pigments, dyes, essential oils, foaming agents, flavors, preservatives (e.g., antioxidants) and the like.
- the solute component thus provides to the composition a near-neutral pH, typically from 6 to 8, and a moderate amount of osmotically active solutes, often having an effective solute concentration of no more than 250 mOsm/L and commonly no more than 200 mOsm/L. Some embodiments include no more than 0.5% (w/v) of one or more anionic surfactants, while others include no added surfactant(s).
- the composition also includes a relatively small amount of one or more effective enzymes.
- composition can be prepared in a number of ways. Description of an exemplary method follows.
- Each of the solute subcomponents other than the enzyme(s) can be added to sufficient water to constitute 60-90% of the calculated desired volume.
- This solution can be stirred and/or heated if desired.
- the desired amount of organic liquid(s) and enzyme(s) then can be added.
- stirring, if used, is complete, sufficient water is added so as to bring the composition to the calculated tonicity and pH value.
- no special conditions or containers are needed to store the composition for an extended time, although refrigeration can be used if desired.
- the composition conveniently can be provided as a solution, although other forms might be desirable for certain end-use applications. Accordingly, the composition can provided as a soluble powder (for subsequent dilution, an option which can reduce transportation costs), a slurry or emulsion, or a thicker form such as a gel (including hydrogels, organogels and xero-gels) or paste (i.e., a suspension in an organic base such as a fatty acid), either of which might be particularly useful for providing increased residence times.
- the composition can include additional ingredients such as a coalescent (e.g., polyvinylpyrrolidone). Salves or ointments, aerosols, foams, and even suspensions also are possible.
- composition described herein is an ability to detach biofilms from the tissues to which they are attached. Regardless of whether this occurs, the composition can significantly reduce the number of viable bacteria remaining on or around the affected tissue.
- compositions can provide large reductions in the number of bacteria, even with extremely short residence times. For example, a 1, 2, 3 or 4 log (99.99%) reduction in the number of bacteria in an entrenched biofilm with a 3, 4, 5, 7, 8, 9, or 10 minute residence time is possible.
- the composition can act at least in part to interrupt or break ionic crosslinks in the macromolecular matrix of a biofilm, facilitating the passage of solutes and surfactant through the matrix to bacteria entrained therein and/or protected thereby.
- Disruption of the macromolecular matrix advantageously also can result in detachment of the biofilm, alternatively or in addition to treating bacteria entrained in that matrix.
- the composition exhibits efficacy against bacterial forms other than biofilms and against microbes other than bacteria.
- the composition can kill and/or prevent growth of microbes, regardless of their phase of life cycle.
- each of the lag phase (metabolic protein production), log phase (reproduction) and stationary phase (approximately equal amounts of dying, metabolizing and reproducing bacteria) of a bacterium's lifecycle technically constitutes an “active” phase. Regardless of whether an individual bacterium is dormant, reproducing, or metabolizing, the composition can kill it or prevent it from growing.
- Bacteria that are part of biofilms often are dormant (not metabolizing or reproducing), and this lack of cellular processes (inactivity) often provides resistance to antibiotics, which require active metabolism or reproduction for efficacy, and other active antimicrobials.
- compositions technically are not living microbes because they require a host for reproduction. Nevertheless, the composition is capable of disrupting, penetrating and/or dissolving the protein coating(s) on a virus.
- the ability to attack these protective structures means that the composition exhibits efficacy against a virus before it ever achieves the ability to reproduce after cellular infection.
- Ciliotoxicity generally increases with increasing surfactant concentration, increasing tonicity, and/or departure of pH from neutral. Given the foregoing description, the ordinarily skilled artisan can provide a ciliacompatible composition that remains effective against microbes in biofilm form.
- composition can be employed in a variety of ways.
- the composition can be delivered to the targeted areas of the ear during and/or after surgery. This might be as simple as washing or rinsing the outer surface of a tympanic membrane, for example, one on which a surgical procedure is to be performed. (In such cases where the composition is not expected to pass the tympanic membrane, a composition with more aggressive pH and tonicity values can be employed.) For procedures involving access of the middle/inner ear, the composition can be delivered through a tympanostomy tube or via syringe inserted through a perforation or incision in the tympanic membrane. In both cases, a medical professional can continue to insert composition until liquid backflow is observed. (A typical human middle ear holds 1 to 1.5 mL of liquid, by way of example.)
- the composition can be introduced to the sinus cavity via a surgical technique such as trephination or via a remote delivery mechanism such as, e.g., a HydrodebriderTM endoscopic sinus irrigation system (Medtronic; Minneapolis, Minn.) or a Relieva VortexTM sinus irrigation catheter (Acclarent, Inc.; Irvine, Calif.).
- a medical profession can continue delivering composition to the targeted cavity(ies) until returning effluent appears visually clear.
- the composition can be permitted a dwell of time of a few seconds up to several hours.
- the targeted dwell time typically depends on the nature of the patient (e.g., ability to be sufficiently immobile to permit a long dwell time) as well as the physiology of the area to be treated, e.g., whether liquid introduced to that area naturally drains or pools.
- flushing or rinsing of the treated area typically is not necessary, although irrigation with a liquid such as a normal saline solution certainly is possible.
- the antimicrobial composition also or alternatively can be used to provide sterility to pre- and post-surgical articles such as sponges, topical wipes, bandages, pads, gauze, surgical packing, and the like, particularly those intended or expected to contact cilia-containing tissue.
- tympanostomy tubes can become colonized, prior to and during implantation, with bacteria from the environment, from a healthcare worker, or more commonly from bacteria present on the patient's own skin. After insertion, these implants can become colonized from systemic bacteria which make their way to the implant which provides a surface for biofilm growth because the implant surface is not protected by the host immune defenses.
- currently employed sterilization techniques are not designed to remove EPS/ECPS, the presence of which greatly facilitates formation of a biofilm; therefore, even a sterilized device/article that is properly implanted can have EPS/ECPS on its surface from previous exposure.
- the aforedescribed antimicrobial compositions can be effective topical treatments, applied to a to-be-implanted device or article or can be used to wash the infected implant and surrounding tissue to rid the body of a biofilm and/or biofilm-forming materials such as EPS/ECPS.
- the tympanic membrane where the implant is or was located likewise can be treated with the previously described composition. This can be done at the time of the original implantation (i.e., immediately following insertion of the article), and can be followed with rinsing/irrigation, suctioning or both.
- deciliation is a significant concern for any composition that is intended for use in the sinus cavities and, particularly, the middle-inner ear. While deciliation is preferably avoided altogether, no more than ⁇ 20%, preferably no more than ⁇ 15%, and more preferably no more than ⁇ 10%, is acceptable for compositions intended for use in sinus applications. For otic compositions, the acceptable upper limit is that which results in measurable hearing loss. Deciliation can be determined via scanning electron microscopy, as described more fully below, and/or audiometric testing.
- the relative efficacy of treating compositions was determined using a MBEC high throughput screening assay, similar to that used in the procedure described in ASTM E2799-12 (Standard Test Method for Testing Disinfectant Efficacy against Pseudomonas aeruginosa Biofilm Using the MBEC Assay).
- the assay employed a multiwell assembly 10 of the type shown in FIG. 1 , which includes plate 12 having multiple wells 14 and lid 16 having multiple pegs 18 .
- Each of plate 12 and lid 16 is made of a plastic such as polystyrene or polycarbonate.
- Bacteria is propagated in one or more of multiple wells 14 immediately after a plate 12 is removed from sterile packaging.
- the plate included 96 wells in an array of 8 rows and 12 columns, as graphically represented in FIG. 2 .
- the five wells represented by D 12 -H 12 served as bacterial growth controls.
- the bacteria used were S. aureus , ATCC 33592 (MRSA), and P. aeruginosa , ATCC 15442.
- the surface of appropriate agar media were inoculated with a recently grown stock culture of each bacteria.
- An isolated colony was aseptically removed from the plate and inoculated with 200 mL of soybean-casein digest medium; flasks were incubated at 35° ⁇ 2° C. and 150 ⁇ 10 rpm (18-24 hours for staph, 16-18 hours for pseudomonas ) with viable bacterial densities being targeted at ⁇ 10 8 CFU/mL, checked by serial dilution and plating.
- Lid 16 was placed on plate 12 , and assembly 10 was labeled before being placed onto an orbital incubator/shaker set to 110 ⁇ 10 rpm.
- the incubator/shaker was allowed to run at 35° ⁇ 2° C. for the amount of time noted previously as being appropriate for each bacterium type.
- the bacterial growth pegs (D 12 -H 12 in FIG. 2 ) were broken off using flame sterilized pliers held flush against lid 14 . Each of those five pegs was placed into a separate sterile microcentrifuge tube with 1.0 mL phosphate-buffered saline (PBS). The microcentrifuge tubes then were placed on a stainless steel tray floated in the center of a sonication device; the tray was permitted to sonicate for 1800 ⁇ 300 seconds. After sonication, the solution in each microcentrifuge tube was serially diluted by transferring 0.1 mL into a new sterile microcentrifuge tube containing 0.9 mL PBS. The dilutions were spot plated onto agar appropriate for the particular bacterium being tested.
- PBS phosphate-buffered saline
- One plate designated the “Challenge Plate,” is graphically depicted in FIG. 3 , where the symbols represent the following:
- the Challenge Plate was placed into a humidified incubator set at 36° ⁇ 1° C. for at least 60 minutes.
- the Challenge Plate was removed from the incubator.
- the Growth Plate peg lid was rinsed for ⁇ 10 seconds to remove any planktonic microbes and transferred onto the Challenge Plate before the combination was incubated at 36° ⁇ 1° C. for the appropriate time described above. Thereafter, the peg lid was transferred to the Recovery Plate.
- From the Challenge Plate was transferred 100 ⁇ L of the contents from each well of row A into the corresponding row A well of the Quantification Plate 1 , 100 ⁇ L of the contents from each well of row D into the corresponding row A well of the Quantification Plate 2 , and 100 ⁇ L of the contents from each well of row G into the corresponding row A well of the Quantification Plate 3 .
- the Recovery Plate was placed in the stainless steel tray of the sonicating device and permitted to sonicate for 1800 ⁇ 300 seconds.
- Dilution Plates 1 - 3 were prepared by adding 180 ⁇ L PBS into the wells of rows B-H of new 96-well multiwells. Following sonication, 100 ⁇ L of the contents from each well of row B of the Recovery Plate were transferred into the corresponding well of row A of Dilution Plate 1 . Serial dilutions (10° 40 were achieved by transferring 20 ⁇ L down each of the 8 rows, e.g., 20 ⁇ L from cell A 1 was put into B 1 , diluted and mixed, 20 ⁇ L from cell B 1 was put into C 1 , diluted and mixed, etc. The contents of each well of Dilution Plate 1 were mixed by pipetting up and down, with the pipette tip being discarded after mixing each row. The dilution series from the Dilution Plate 1 was spot plated on appropriate agar for viable cell counts, described below.
- Quantification Plates 1 - 3 were treated similarly to Dilution Plates 1 - 3 .
- CFU colony forming unit
- V pl is the plated volume in ⁇ L
- V w is the volume of a plate well (here, 200 ⁇ L)
- a pg is the area of a lid peg (here, 46.63 mm 2 )
- x is an integer representing the plate row, i.e., 1 for row A, 2 for row B, 3 for row C, etc.
- the average of the values for each of columns 1-5 were determined, and log reduction was determined by subtracting the average of treated pegs from the average of untreated pegs.
- pegs A 12 -C 12 were checked to ensure that they remained clear, pegs D 12 -H 12 were checked to ensure the presence of 10 4 -10 6 CFU/mm 2 of recovered microbe, column 6 was checked to ensure neutralizer effectiveness, column 7 was checked to ensure neutralizer non-toxicity, and column 8 was checked to ensure microbial growth.
- the ALI model which uses epithelial tissue grown on permeable filter supports submerged in culture medium, was used as a screening test to determine whether the composition employed in Example 2 exhibited significant ciliotoxicity.
- Mucosal specimens acquired from residual clinical material obtained during sinonasal surgery were transported to the laboratory in saline placed on ice.
- ALI cultures were established from human sinonasal epithelial cells enzymatically dissociated human tissue using procedures described at, for example, M. Ramanathan et al., “A comparison of experimental methods in molecular chronic rhinosinusitis research.” Am. J. Rhinol ., vol. 21, pp. 373-77 (2007).
- Beating cilia on the edges of each sample were identified using a Leica DMLFSA microscope set on an air table, using a water immersion 63 ⁇ objective and differential inter-ference contrast optics (Leica Microsystems, Inc.; Bannockburn, Ill.).
- Leica Microsystems, Inc. Bannockburn, Ill.
- Two seconds of video at a sampling rate of 100 frames/second were captured with a high-speed monochromatic digital video camera (Basler AG; Ahrensburg, Germany), with the video images being routed into a PC workstation for compression and storage. This process was repeated at 1-minute intervals, with a 5-minute baseline beating rate being determined before 20 ⁇ L of the composition from Example 2 was pipetted onto the apical surface of the mucosal sample and video imaging was continued.
- Image files were analyzed with virtual instrumenta-tion software customized to analyze ciliary beating. (For more information on this type of video image analysis technique, see J. H. Sisson et al., “All-digital image capture and whole-field analysis of ciliary beat frequency,” J. Microscopy , vol. 211, pp. 103-11 (2003).)
- the targeted result was a finding that at least 50% of cilia (as measured by active area) would continue beating through 30 minutes of exposure of a sample to the composition.
- the actual results of the testing are shown in FIG. 4 .
- the median active area for the baseline period was ⁇ 24.3%, while the median active area as measured at 30-33 minutes was ⁇ 16.4%. Accordingly, the treating composition from Example 2 was deemed to have passed the ALI screening test.
- the beat frequency of the cilia during exposure to the treating composition from Example 2 also was measured, with those results being shown in FIG. 5 .
- the median cilia beat frequency for the baseline testing was ⁇ 4670 Hz, while the median for the solution at 30-33 minutes of exposure was ⁇ 3160 Hz.
- FIG. 5 also indicates that cilia beat frequency continues to increase after exposure.
- the sinus treating composition from Example 2 also was tested on three harvested mouse nasal septa. (Harvesting was conducted as described in the M. B. Antunes et al. article mentioned previously.)
- Each harvested septal explant was held in sterile PBS before being placed in a glass perfusion chamber held in place with a nylon grid (1.5 mm), the outer frame of which snapped into the inside of the perfusion chamber (Warner Instruments; Hamden, Conn.). Each explant was tested at 27.5° to 28.5° C.
- a 3-minute baseline beating rate was determined before each explant sample was given a 3-minute exposure to the sinus treating composition from Example 2.
- the cilia beat frequency values after exposure are greater than those before exposure, indicating no debilitating damage to the cilia of the explant samples.
- the sinus treating composition from Example 2 also was tested on ciliated mucosal surfaces in the sinuses of living rabbits at the University of Sao Paolo.
- indwelling catheters were placed into the maxillary sinuses of female New Zealand white rabbits, with 10 mL (at a rate of 0.33 mL/sec) of either 0.9% normal saline or the treating composition from Example 2 being instilled into the sinuses, followed by aspiration.
- Test rabbits were anaesthetized and killed either one day or seven days after irrigation.
- the 7-day timeframe permits evaluation of possible long-term deciliation, while the 1-day timeframe guards against the possibility of immediate deciliation followed by regrowth in the intervening six days. (Sinus cilia often regrow within 48 hours of being lost.)
- Mucosa from both left and right maxillary sinuses were harvested, with each mucosa sample being evaluated by scanning electron microscopy (SEM) for morphological integrity of the epithelium.
- SEM scanning electron microscopy
- Ototoxicity testing was conducted by the Department of Otolaryngology in the University of Florida College of Medicine, employing internally approved animal handling/testing procedures which conform to the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
- each of eight mature, albino male guinea pigs (Charles River; Wilmington, Mass.) underwent a bilateral myringotomy, conducted with a blunt 27 gauge sterile needle. Sufficient liquid was injected so as to fill the animals' middle ear spaces ( ⁇ 0.2 mL), with one ear receiving a control 0.9% normal saline solution and the other receiving the treating composition from Example 1. After injection, the dorsal skull of each animal was tapped gently to ensure thorough exposure of the entireties of the animal's middle and inner ears to the liquids.
- Cochlear action potential for each animal was measured before solution injections, 7 days after injection, and 28 days after injection, using electrocochleography as described by T. M. Lo et al., “Hearing loss with stapedotomy and treated otitis media,” Otolayngol. Head Neck Surg ., vol. 134(4), pp. 674-79 (April 2006).
- Electrocochleographic thresholds were measured for calibrated tone bursts generated by an auditory electrophysiology workstation using software from Tucker-Davis Technologies (Gainesville, Fla.) and electrostatic speakers. Stimuli were introduced through insert headphones placed in the animal's external auditory canal.
- Tone bursts at frequencies of 4 kHz, 8 kHz, 16 kHz and 24 kHz were presented. Beginning at 100 dB, auditory thresholds were evaluated by decreasing stimulus intensity in 5 dB decrements until disappearance of the waveform. Waveforms were averaged in response to 512 tone bursts at each tested frequency/amplitude combination.
- Hearing thresholds for each ear were compared using a paired, two-tailed t-test (SAS Institute Inc.; Cary, N.C.). Significance levels were determined at p ⁇ 0.05.
- each animal was euthanized so that their cochlea could be examined by SEM so as to assess outer hair cell (OHC) loss.
- OOC outer hair cell
- Example 1 Based on both the comparative hearing data and the SEM analysis, the report concluded that the treating composition employed in Example 1 did not cause ototoxicity. The results were deemed to be sufficiently definitive that a follow-on confirmative study employing chinchillas was recommended to be foregone.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Otolaryngology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A composition that can be used to treat a wide spectrum of gram positive and gram negative bacteria, including but not limited to those in biofilm form, and other microbes can be used in cilia-containing areas such as the sinus cavities and middle/inner ear, while resulting in no, or very minimal amounts of, deciliation. Where such a targeted treatment area includes a biofilm, the composition often can detach and assist in removing the biofilm from affected tissue. Many embodiments of the composition are biocompatible.
Description
- This is a continuation of U.S. patent application Ser. No. 16/314,168, having a 35 U.S.C. § 371(c) date of 28 Dec. 2018 and issued as U.S. Pat. No. 11,090,369 on 17 Aug. 2021, which was a national stage entry of international application PCT/US2017/039836, filed 28 Jun. 2017, which claims priority to U.S. provisional patent application nos. 62/357,147, filed 30 Jun. 2016, and 62/524,522, filed 24 Jun. 2017, which are incorporated herein by reference.
- Microbes are found virtually everywhere, often in high concentrations, and are responsible for a significant amount of disease and infection. Eliminating these microorganisms from targeted tissues is often desirable and sometimes critically important.
- Bacteria present special challenges because they can exist in a number of forms, including planktonic, spore and biofilm, and their various self-preservation mechanisms make treating and/or eradicating them extremely difficult. For example, the bacteria in biofilms or spores are down-regulated (sessile), making them resistant to attack by a large group of antibiotics and antimicrobials that are effective only during the active parts of a bacterium's lifecycle, e.g., cell division.
- In a biofilm, microbes such as bacteria or fungi interact with and adhere to surfaces, forming colonies which facilitate continued growth. The microbes produce exopoly-saccharide (EPS) and/or extracellularpolysaccharide (ECPS) macromolecules that keep them attached to a surface and form a protective barrier effective against many forms of attack. The small diameter of flow channels in the EPS/ECPS macromolecular matrix, which restricts the size of molecules that can reach the underlying microbes, and consumption of biocides through interactions with portions of the EPS/ECPS macromolecular matrix and microbe secretions and waste products contained therein probably play roles in the protective barrier function.
- Due to the protection afforded by the macromolecular matrix and their down-regulated state, microbes in a biofilm state are very difficult to treat. The types of biocides and antimicrobials effective in treating microbes in this form often are strongly acidic or caustic, and often oxidizing due to the presence of halogen atoms, oxygen atoms, or both. Large dosages of such chemicals must be allowed to contact the biofilm for extended amounts of time to be effective, which makes them impractical for many applications.
- Compositions intended for use in connection with compromised animal/human tissue which solvate a biofilm matrix so that it can be rinsed or otherwise removed from infected tissue have been described in, e.g., U.S. Pat. Nos. 7,976,873, 7,976,875, 7,993,675, and 7,959,943. Compositions based on similar components but intended for other uses have been described in U.S. Pat. Nos. 8,940,792 and 9,314,017 and U.S. Pat. Publ. Nos. 2010/0086576, 2014/0242188, and 2016/0073628.
- However, animal testing has shown that compositions such as those described in the preceding paragraph, when applied to ciliated tissue such as exist in the sinus cavities and inner ear, tend to result in deciliation, i.e., the loss in functionality and/or removal of cilia, which are the relatively thick protruding organelles found in and projecting from the bod of eukaryotic cells. Sinus cavity cilia facilitate clearance of the sinuses, while those in the ear act as sound receptors.
- Testing suggests that contributing factors in deciliation likely include the presence of ionic surfactants, high effective solute concentrations, and pH. Unfortunately, compositions described in the documents listed in the preceding paragraph all call for at least 0.2% (w/w) surfactant, and many require or prefer low pH and very high effective solute concentrations, i.e., osmolarities.
- Because biofilms deciliate affected tissue anyway and because cilia in the sinus cavities can regrow within days, limited deciliation which does not impede clearing of the sinuses might be an acceptable side effect in a product intended for use in those sinus cavities not connected to the inner ear via a Eustachian tube. However, compositions intended for use in treating portions of the ear inward of the tympanic membrane (or treating a sinus cavity that is connected to the inner ear) cannot be permitted to result in deciliation because inner ear cilia do not regrow, resulting in irreparable hearing loss.
- That which is desirable is a composition that can effectively treat microbes present in cilia-containing areas such as the sinus cavities and middle/inner ear, particularly microbes in a biofilm form, without resulting in unacceptable levels of deciliation. A composition that can accomplish the foregoing while also causing or facilitating detachment of biofilms from affected tissue is particularly desirable.
- Such an antimicrobial composition that can be provided in a variety of viscosities and introduced to the targeted area via more than one delivery route is particularly desirable.
- Further desirable is a composition that is sufficiently biocompatible so as to not require removal via irrigation using, for example, a saline rinse.
- The present invention is directed to compositions that can be used to treat microbes including but not limited to bacteria, including those in biofilm form. The term “treat” includes killing, inactivating and/or removal.
- A composition according to the present invention is effective against a wide spectrum of gram positive and gram negative bacteria and exhibits lethality toward other microbes such as viruses, fungi, molds, and yeasts.
- Advantageously, this composition can effectively kill microbes present in cilia-containing areas such as the sinus cavities and middle/inner ear, even microbes in a biofilm form, while resulting in no, or very minimal amounts of, deciliation. Where such a targeted treatment area includes a biofilm, the composition often can detach and assist in removing the biofilm from affected tissue.
- The composition typically is provided as a liquid having a viscosity similar to that of water, but can be thickened to provide a variety of forms with a range of viscosities. It also can be delivered via techniques employing a variety of presently available equipment.
- All embodiments of the composition are biocompatible, while many embodiments are ciliacompatible.
- The composition has a near-neutral pH, typically from 6 to 8, and includes a moderate amount of osmotically active solutes, often having an effective solute concentration of no more than 400 mOsm/L, commonly no more than 250 mOsm/L and more commonly no more than 200 mOsm/L. Embodiments intended for use in the sinus cavities can include no more than 1.0, 0.8, 0.7 or 0.5% (w/v) of one or more anionic surfactants, while other embodiments intended for use in the middle or inner ear can include no added surfactant(s). The composition includes at least 2% (w/v) of one or more non-aqueous liquids, with the upper limit determined in large part by the intended end use of the composition. The composition also includes at least 0.005% (w/v) of one or more enzymes which are active at 6≤pH≤8 so as to facilitate microbial cell wall rupture by catalyzing and/or easing the breaking of chemical bonds present in or between molecules in those cell walls. (Because enzymes vary so widely in terms of chemical structure and targeted utility, the upper limit often is based on the amount of a particular enzyme, if any, that results in a level of ciliotoxicity deemed to be unacceptable for a particular end use.)
- The composition is effective at interrupting or breaking ionic crosslinks in the macromolecular matrix of a biofilm, which facilitates passage of the solutes, surfactant (if present) and enzyme through the matrix to the microbes (e.g., bacteria) entrained therein and/or protected thereby. The composition thus bypasses and/or disables the biofilm defenses, allowing previously protected microbes to be accessed and killed, typically by processes that include inducing membrane leakage in bacteria, leading to cell lysis.
- Also provided are methods for treating affected areas including application of non-solid compositions can be applied to an affected area. The composition can be non-flowing if intended to be left in place or can be a liquid if intended to irrigate or otherwise flow over or around a treatment area.
- Embodiments of the composition can be used to treat chronic otitis media, cholesteatoma and other bacterial ear conditions, as well as chronic rhinosinusitis and other bacterial sinus conditions.
- Often, a flowable form of the composition is introduced peri- or post-surgery performed on an affected area. For example, a composition can be introduced into the middle ear via a tympanostomy tube immediately or soon after its insertion or, if deemed necessary desirable, during a post-surgical follow-up evaluation.
- To assist in understanding the following description of various embodiments, certain definitions are provided immediately below. These are intended to apply throughout unless the surrounding text explicitly indicates a contrary intention:
-
- “comprising” means including but not limited to those ingredients which follow the term;
- “consisting of” means including only those ingredients which follow the term as well as minor amounts of inactive additives or adjuvants;
- “consisting essentially of” means including only the listed ingredients, minor amounts (less than 2%, 1%, 0.5%, 0.25%, or 0.1%, all w/v) of other ingredients that supplement the antimicrobial activity and/or provide a secondary effect (e.g., antifogging, soil removal, wound cleaning, etc.) that is desirable in view of the intended end use, and/or inactive additives or adjuvants;
- “microbe” means any type of microorganism including, but not limited to, bacteria, viruses, fungi, viroids, prions, and the like;
- “antimicrobial agent” means a substance having the ability to cause greater than a 90% (1 log) reduction in the number of one or more of microbes;
- “active antimicrobial agent” means an antimicrobial agent that is effective only or primarily during the active parts of a microbe's lifecycle, e.g., cell division, and the activity of which involves disruption of a cellular process;
- “biofilm” means a community of microbes, particularly bacteria and fungi, attached to a surface with the community members being contained in and/or protected by a self-generated macromolecular matrix;
- “entrenched biofilm” means a biofilm that has reached a steady state mass after a growth period of two or more days;
- “buffer” means a compound or mixture of compounds having an ability to maintain the pH of a solution to which it is added within relatively narrow limits;
- “buffer precursor” means a compound that, when added to a mixture containing an acid or a base, results in a buffer;
- “polyacid” means a compound having at least two carboxyl groups and specifically includes dicarboxylic acids, tricarboxylic acids, etc.;
- “solvate” means the process of taking a solid material into solution in a liquid;
- “sequestering agent” means a chemical that assists in solvating a compound and in preventing the solvated form of that compound from coming out of solution;
- “metal ion sequestering agent” means a sequestering agent that works in connection with one or more metal ions, particularly alkali and alkaline earth metals;
- “chronic otitis media” means otitis media with effusion or recurrent otitis media;
- “soil load” means a solution of one or more organic and/or inorganic substances added to the suspension of a test organism to simulate the presence of body secretions, excretions, and the like;
- “inoculum” means a solution containing bacteria, growth solution (e.g., tryptic soy broth) and protein soil load; and
- “substituted” (in reference to a functional group) means containing a heteroatom or functionality (e.g., hydrocarbyl group) that does not interfere with the intended purpose of the group in question.
- “dwell time” means the amount of time that an antimicrobial agent is allowed to contact a bacterial biofilm;
- “biocompatible” means presenting no significant, long-term deleterious effects on or in a mammalian species;
- “ciliotoxic” means resulting in significant cleavage or loss of function of cilia; and
- “ciliacompatible” means not ciliotoxic.
- Hereinthroughout, pH values of a liquid are those which can be obtained from any of a variety of potentiometric techniques employing a properly calibrated electrode, and effective solute concentrations preferably are determined by latent heat of fusion calculations from a properly calibrated DSC unit-produced scan acquired over a temperature range that includes the melting temperature of a given liquid composition.
- Any numerical limitation used herein includes an appropriate degree of uncertainty based on the number of significant places used with that particular numerical limitation. For example, “up to 5.0” can be read as setting a lower absolute ceiling than “up to 5.”
-
FIG. 1 is a perspective, schematic view of a disassembled simplified multiwell array, of the type employed in a minimum biofilm eradication concentration (MBEC) high throughput screening assay. -
FIG. 2 is a top view of an 8×12 multiwell array employed in the testing of treating compositions of the present invention. -
FIG. 3 is a top view of a challenge plate matrix employed in the testing of treating compositions of the present invention. -
FIGS. 4 and 5 depict Air-Liquid Interface (ALI) model ciliotoxicity testing results for a sinus treatment composition, with active cilia area plotted against time inFIG. 4 and cilia beat frequency plotted against time inFIG. 5 . -
FIG. 6 depicts averaged baseline hearing threshold data for eight guinea pigs. -
FIGS. 7 and 8 depict averaged threshold shifts in hearing for eight guinea pigs, withFIG. 7 being based on data collected 7 days after liquid insertion andFIG. 8 being based on data collected 28 days after liquid insertion. - Compositions such as those summarily described in the preceding section can be used to break down, remove and/or disrupt biofilms including, advantageously, bacterial biofilms located in the middle or inner ear or the sinus cavities of an animal, particularly a mammal. The compositions are biocompatible and safe to use in and around the delicate tissues and structures of those areas because they are free of constituent materials which might harm such tissues or structures or unduly compromise long-term hearing.
- Embodiments of the composition have a sufficiently low viscosity to enable delivery using techniques such as spray application, lavage, misting, mopping, wicking and dripping. These and other embodiments of the composition also can be easily removed from the treatment site by subsequent flushing, rinsing, and draining, although many such embodiments are sufficiently biocompatible to allow for absorption.
- While not wishing to be bound by theory, a metal ion sequestering agent in the composition might complex or otherwise bond with metal ions which crosslink, bridge or otherwise assist in binding together polymer chains in the EPS/ECPS matrix of a biofilm. Other components of the composition then might surround the unbound polymer chains or fragments, breaking down the matrix, solvating the uncrosslinked polymer chains or fragments, and bringing them into solution or suspension so that they can be flushed or otherwise removed from the treatment area using, for example, additional amounts of the solvating system or a separate rinsing agent.
- The composition includes solvent and solute components.
- The solvent component of the composition includes water and at least one non-aqueous liquid.
- Water has a high solute holding capability, good wetting properties, excellent biocompatibility, environmental friendliness, and low cost. Essentially any source of water can be used, although those that are relatively free of bacteria without advance treatment are preferred. The water need not be distilled, deionized, or the like, although such treatments certainly are not excluded, particularly where the water employed might include undesirable solutes which might interfere with the intended purpose of the composition. To enhance solubility of one or more of the other components of the composition, the water can be heated.
- The one or more non-aqueous liquids typically has/have a δp value no higher than that of water, where δp is the dipolar intermolecular force (polarity) Hansen Solubility Parameter (HSP), a common method for predicting whether one material will dissolve in another to form a solution; the HSP values for most commonly used solvents are well documented.
- Each component in a mixture or composition has three HSPs: dispersion, dipole-dipole (polarity) interactions, and hydrogen bonding. These parameters are generally treated as coordinates in three dimensions, with HSP characterizations being visualized using a spherical representation: the 3D coordinates are at the center of the sphere with the radius of the sphere (R0 or “interaction radius”) indicating the maximum difference in affinity tolerable for a “good” interaction with a solvent or solute. In other words, acceptable solvents lie within the interaction radius, while unacceptable ones lie outside it.
- The distance between the HSPs of two materials in so-called Hansen space (Ra) can be calculated according to the following formula:
-
(R a)2=4(δd2−δd1)2+(δp2−δp1)2+(δh2−δh1)2 (I) - where δd is the energy from dispersion forces between the molecules, δp is the energy from dipole-dipole intermolecular forces, and δh is the energy from hydrogen bonds between molecules.
- A simple composite affinity parameter, the Relative Energy Difference (RED), represents the ratio of the calculated HSP difference (Ra) to the interaction radius (R0), i.e., RED=Ra/R0. In situations where RED<1.0, the solubilities of the molecules are sufficiently similar that one will dissolve in the other. In situations where RED<1.0, the solubilities of the molecules are not sufficiently similar for one to dissolve the other. In situations where RED 1.0, partial dissolution is possible.
- The dipole-dipole interaction Hansen solubility parameter for a particular solution or mixture of solvents can be calculated according to the following formula:
-
- where δdi is the energy from dipolar intermolecular force for solvent i, xdi is the percentage of solvent i in the solvent portion of the composition, and n is the total number of solvent components.
- Hereinthroughout, the δp value for a given solvent or combination of solvents is determined at room temperature (because solubility typically increases with increasing temperature, meaning that the dissolution rate of the macromolecular matrix and the bacterial cell wall proteins will increase, the efficacy of the inventive composition is expected to increase at higher temperatures) and pH values are those which can be obtained from any of a variety of potentiometric techniques employing a properly calibrated electrode.
- More details about HSPs and related concepts can be found US Pat. Publ. No. 2016/0073628.
- The solvent component of the composition includes at least one non-aqueous liquid, typically one with a δp value no higher than that of water (δp≈16.0 MPa1/2). Exemplary composition intended for use in a sinus application can employ 5-20% (w/v) dimethyl sulfoxide (DMSO) with an overall δp≈16.0 MPa1/2, while exemplary compositions intended for use in an otic application can employ 5-15% (w/v) ethanol with an overall δp 15.4 MPa1/2.
- In certain embodiments, preference can be given to those organic compounds which are, or can be made to be, highly soluble in water and to those which are ciliacompatible. Additionally, preference can be given to any organic liquid that has been deemed to be safe and “inactive” (by regulatory bodies) at intended usage levels.
- The composition includes at least 2% (w/v) of one or more non-aqueous (organic) liquids, with the upper limit determined in large part by the intended end use of the composition, i.e., the upper limit for sinus applications probably is higher than that for otic applications. In some embodiments, the lower limit can be 2.1, 2.2, 2.3, 2.4 or even 2.5%, with all of the foregoing being presented in w/v format. Exemplary ranges include 2.25-15% (sinus) or 2.0-10% (otic), with typical ranges being 2.5-13% (sinus) and 2.1-9% (otic) and preferred ranges being 2.5-12.5% (sinus) and 2.2-8% (otic), again with all of the forgoing being presented in w/v format.
- In addition to the solvent component, the composition also includes as a primary component a solute component which can contain as few as two sub-components: the dissociation product(s) of at least one metal ion sequestering agent and at least one effective enzyme. In embodiments not intended for otic applications, anionic surfactant also can be included. The dissociation product(s) of one or more salts also can be included to increase effective solute concentration. Each of the foregoing ingredients generally is considered to be biocompatible.
- The metal ion sequestering agent can be an acid or base capable of complexing or otherwise reacting with one or more metal ions in the EPS/ECPS matrix of a biofilm. Metal ions of particular interest, due to their likely involvement in the targeted biofilms, include sodium, calcium and iron. The metal ion sequestering agent desirably is water soluble, nontoxic and not prone to aggravate long-term hearing loss.
- Acids generally are preferred over bases, although either type of sequestering agent can be used. Preference can be given to those metal ion sequestering agents which are biocompatible. Alternatively or additionally, preference can be given to those metal ion sequestering agents which can act to chelate the metallic cations ionic involved in crosslinking the macromolecular matrix of a biofilm. The metal ion sequestering agent preferably is not considered to be an oxidizer, particularly if it is an acid. Additionally, strong preference can be given to those acids and bases that have been deemed to be safe or “inactive” (by regulatory bodies) at intended usage levels
- Acidity is achieved by adding to water (or vice versa) one or more acids, specifically strong (mineral) acids such as HCl, H2SO4, H3PO4, HNO3, H3BO3, and the like or, preferably, weak acids, particularly organic acids and, preferably, organic polyacids. Examples of organic acids include monoprotic acids such as formic acid, acetic acid and substituted variants, propanoic acid and substituted variants (e.g., lactic acid, pyruvic acid, and the like), any of a variety of benzoic acids (e.g., mandelic acid, chloromandelic acid, salicylic acid, and the like), glucuronic acid, and the like; diprotic acids such as oxalic acid and substituted variants (including oxamic acid), butanedioic acid and substituted variants (e.g., malic acid, aspartic acid, tartaric acid, citramalic acid, and the like), pentanedioic acid and substituted variants (e.g., glutamic acid, 2-ketoglutaric acid, and the like), hexanedioic acid and substituted variants (e.g., mucic acid), butenedioic acid (both cis and trans isomers), iminodiacetic acid, phthalic acid, ketopimelic acid, and the like; triprotic acids such as citric acid, 2-methylpropane-1,2,3-tricarboxylic acid, benzenetricarboxylic acid, nitrilotriacetic acid, and the like; tetraprotic acids such as prehnitic acid, pyromellitic acid, and the like; and even higher degree acids (e.g., penta-, hexa-, heptaprotic, etc.). Where a tri-, tetra-, or higher acid is used, one or more of the carboxyl protons can be replaced by cationic atoms or groups (e.g., alkali metal ions), which can be the same or different. Preferred acids include mono-, di- or tri-protic citric acid, acetic acid, octanoic acid and glutamic acid.
- Basicity is achieved by adding to water (or vice versa) one or more bases such as, but not limited to, alkali metal salts of weak acids including acetates, fulmates, lactates, phosphates, and glutamates; alkali metal nitrates; alkali metal hydroxides, in particular NaOH and KOH; alkali earth metal hydroxides, in particular Mg(OH)2; alkali metal borates; NH3; and alkali metal hypochlorites (e.g., NaClO) and bicarbonates (e.g., NaHCO3). Again, preference is given to those compounds which are, or can be made to be, soluble in water and which are biocompatible.
- The concentration of metal ion sequestering agent added to water, or vice versa, is relatively unimportant because of the targeted effective solute concentration and hydronium ion concentration, i.e., 6≤
pH≤ 8. Thus, use of a strong acid or base militates against addition of large amounts of that acid/base. Additionally, the relatively moderate effective solute concentration limits (discussed below) argue against significant amounts of buffer precursor. Conversely, use of a very weak acid or base permits addition of a much larger amount of the acid/base and/or a much reduced amount of a buffer precursor. - Each of U.S. Pat. Nos. 8,940,792 and 9,314,017, as well as U.S. Pat. Publ. Nos. 2010/0086576, 2014/0242188, and 2016/0073628, suggests that a decrease or increase (depending on whether an acid or base is used) in pH generally corresponds with enhanced efficacy. However, because the present composition is desired to be biocompatible and have minimal ciliotoxicity, the targeted pH range is one log unit either side of neutral. Thus, a key efficacy-enhancing variable from those prior teachings is not available in compositions of the present invention. The present composition has a targeted pH (t) which generally is on the order of t=6.5±v or t=7.5±v where v represents 0.4, 0.3, 0.25, 0.2, 0.15, 0.1 or 0.05.
- The amount(s) of acid(s) or base(s) necessary to reach a given t value will, of course, depend on the strength of the particular acid(s) or base(s) used. Because even small amounts of those compounds considered to be weak acids or bases will adjust a composition's pH, respectively, below or above the aforementioned t values, the solute component almost always includes sufficient amounts of a buffer precursor (discussed below) so as to provide a composition having a desired t.
- In addition to metal ion sequestering agent, each of the documents set forth in the preceding paragraph requires moderate-to-high levels of one or more surfactants. Because the compositions of the present invention are intended to be used in the presence of cilia and because many types of surfactant are known to be ciliotoxic, inclusion of surfactants is contraindicated. For embodiments of the composition intended for otic applications, this means that separately added surfactants are avoided altogether or strictly limited (e.g., less than 0.5, 0.41, 0.33, 0.25, 0.21, 0.17, 0.13, 0.09 or 0.05%, all w/v), while very limited amounts of one or more anionic surfactants can be included in embodiments intended for sinus applications. Again, this means that an efficacy-enhancing option from the aforementioned prior teachings is not available (or much less available) in compositions of the present invention
- The amount of anionic surfactant to be included in embodiments intended for use in sinus-related applications generally is less than 1.0%, commonly less than 0.75%, typically less than 0.5%, preferably less than 0.4%, more preferably less than 0.35%, and most preferably less than 0.3%, all presented in w/v format. Where one or more anionic surfactant(s) is/are included in a sinus-targeted composition, the total amount present generally is from 0.02 to 0.67%, commonly from 0.03 to 0.55%, typically from 0.04 to 0.42%, preferably from 0.05 to 0.39%, even more preferably from 0.06 to 0.36%, and still more preferably from 0.08 to 0.33%, all again w/v.
- Potentially useful anionic surfactants include, but are not limited to, sodium chenodeoxycholate, N-lauroylsarcosine sodium salt, lithium dodecyl sulfate, 1-octanesulfonic acid sodium salt, sodium cholate hydrate, sodium deoxycholate, sodium dodecyl sulfate, sodium glycodeoxycholate, sodium lauryl sulfate, and the alkyl phosphates set forth in U.S. Pat. No. 6,610,314.
- The enzyme sub-component of the solute component can be any one or more which is/are capable of facilitating microbial cell wall rupture by catalyzing and/or easing the breaking of chemical bonds present in or between molecules in those cell walls. One category believed to be particularly effective is glycosidase, particularly the species lysozyme. Testing to date has shown that lysozyme exhibits some efficacy at amounts as low as 80 ppm, i.e., 0.08 g lysozyme per kg of composition. Commonly employed amounts of enzyme(s) are at least 100 ppm, at least 125 ppm, and at least 150 ppm. Exemplary ranges include 85 to 500 ppm, 90 to 450 ppm, 95 to 400 ppm, 100 to 350 ppm, 105 to 300 ppm, 110 to 275 ppm, 115 to 250 ppm, 120 to 225 ppm, 125 to 200 ppm, 130 to 190 ppm, 135 to 185 ppm, and 140 to 180 ppm.
- Composition efficacy generally increases with the presence of at least moderate effective solute concentrations, which generally increases in proportion with the amounts of solute subcomponents employed. However, the amounts of two of those subcomponents—metal ion sequestering agent and surfactant—are severely limited.
- To increase the effective solute concentration (tonicity) of a composition, one or more types of other water soluble compounds can be included in the solute component. Such compounds, upon dissociation, increase the effective amount of solutes in the composition without greatly impacting the molar concentration of hydronium and hydroxyl ions.
- Effective solute concentration of a composition can be increased by adding large amounts of ionic compounds, particularly electrolytes; see, e.g., U.S. Pat. No. 7,090,882. Essentially any compound that at least partially dissociates in water and/or the organic liquid(s) employed in the solvent component can be used to achieve this effect, with exemplary compounds including, but not being limited to, phosphates, acetates and any material deemed to be an “inactive ingredient” in injections, gels, creams, lotions, and/or ointments by governmental regulatory bodies.
- A preferred method of increasing composition tonicity is employing a buffer precursor as a subcomponent of the solute component. For example, where the solute component includes one or more acids, one or more salts of those or other acids can be employed as solute subcomponent(s) which, in addition to increasing tonicity of the composition, provides a pH buffer to it. Where x moles of an acid are employed as a subcomponent of the solute component, an excess (e.g., 2x-8x) of one or more salts of that acid can be included as a separate subcomponent. (The same is true for basic compositions, mutatis mutandis.) The identity of the countercation of the acid salt (or counteranion of the base salt) is not particularly important. Where the salt of a polyacid is used as a buffer precursor, all or fewer than all of the carboxyl hydrogen atoms can be replaced; for example, mono-, di- and trisodium citrate all constitute potentially useful buffer precursors but the latter provides a greater theoretical buffering capacity than either of the other two. (Again, the same is true for salts of a polybase, mutatis mutandis.)
- Regardless of how achieved, the tonicity of the composition is moderately high, with an effective solute concentration of from 100 to 300 mOsm/L being common and 200±10 mOsm/L being typical. Embodiments of the composition can exhibit minimum solute concentrations of 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175 or 180 mOsm/L and maximum solute concentrations of 275, 260, 250, 245, 240, 235, 230, 225, 220, 215, 210, 205, 200, 195, 190 or 185 mOsm/L. Ranges based on each of the minimums and each of the maximums are envisioned, with some exemplary options including, but not being limited to, 110 to 275, 125 to 250, 150 to 250, 160 to 240, 160 to 225, 175 to 250, 170 to 240, 170 to 230, 180 to 240, 180 to 235, and 180 to 220 mOsm/L.
- Although unnecessary and typically contraindicated, any of a variety of additives and adjuvants can be included in the solute component to make a composition more amenable for use in a particular end-use application with negatively affecting its efficacy in a substantial manner. Examples include, but are not limited to, fragrances, pigments, dyes, essential oils, foaming agents, flavors, preservatives (e.g., antioxidants) and the like.
- The solute component thus provides to the composition a near-neutral pH, typically from 6 to 8, and a moderate amount of osmotically active solutes, often having an effective solute concentration of no more than 250 mOsm/L and commonly no more than 200 mOsm/L. Some embodiments include no more than 0.5% (w/v) of one or more anionic surfactants, while others include no added surfactant(s). The composition also includes a relatively small amount of one or more effective enzymes. The foregoing can be tabulated as set forth below, with any value in a given row being combinable with any value for each of the other subcomponent:
-
TABLE 1a otic compositions Solute subcomponents metal ion sequestering 0.05-100, 0.1-50, 0.15-25, 0.2-10, 0.5-5 agent(s), g/L surfactant, g/L <2.5, <2, <1.5, <1, <0.5, ~0 enzyme, ppm 60 to 400, 100 to 300, 125 to 250, 150 to 225 other, including salts 0.5-100, 0.6-75, 0.7-50, 0.8-30 1-25 of sequestering agent(s),g/L Tonicity, mOsm/L 100-275, 125-250, 150-225, 175-220 C2-C4 alcohol, % (v/v) 1.8-10, 2.0-9, 2.1-8, 2.2-7, 2.3-6 -
TABLE 1b sinus compositions Solute subcomponents metal ion sequestering agent(s), same as otic g/L surfactant, g/L 3-75, 6-70, 10-65, 12-60, 15-56 enzyme, ppm same as otic other, including salts of 0.5-150, 1-125, 1.5-100, 2-75 3-50 sequestering agent(s), g/L Tonicity, mOsm/L same as otic DMSO, % (v/v) 2.0-20, 2.2-17, 2.3-15, 2.4-13, 2.5-12.5 - Various embodiments of the present invention have been provided by way of example and not limitation. As evident from the foregoing tables, general preferences regarding features, ranges, numerical limitations and embodiments are to the extent feasible, as long as not interfering or incompatible, envisioned as being capable of being combined with other such generally preferred features, ranges, numerical limitations and embodiments.
- The composition can be prepared in a number of ways. Description of an exemplary method follows.
- Each of the solute subcomponents other than the enzyme(s) can be added to sufficient water to constitute 60-90% of the calculated desired volume. This solution can be stirred and/or heated if desired. The desired amount of organic liquid(s) and enzyme(s) then can be added. Once stirring, if used, is complete, sufficient water is added so as to bring the composition to the calculated tonicity and pH value. Advantageously, no special conditions or containers are needed to store the composition for an extended time, although refrigeration can be used if desired.
- The composition conveniently can be provided as a solution, although other forms might be desirable for certain end-use applications. Accordingly, the composition can provided as a soluble powder (for subsequent dilution, an option which can reduce transportation costs), a slurry or emulsion, or a thicker form such as a gel (including hydrogels, organogels and xero-gels) or paste (i.e., a suspension in an organic base such as a fatty acid), either of which might be particularly useful for providing increased residence times. For the latter, the composition can include additional ingredients such as a coalescent (e.g., polyvinylpyrrolidone). Salves or ointments, aerosols, foams, and even suspensions also are possible.
- An advantage of the composition described herein is an ability to detach biofilms from the tissues to which they are attached. Regardless of whether this occurs, the composition can significantly reduce the number of viable bacteria remaining on or around the affected tissue.
- Even where use of a composition does not result in detachment of a biofilm, embodiments of the composition can provide large reductions in the number of bacteria, even with extremely short residence times. For example, a 1, 2, 3 or 4 log (99.99%) reduction in the number of bacteria in an entrenched biofilm with a 3, 4, 5, 7, 8, 9, or 10 minute residence time is possible.
- The composition can act at least in part to interrupt or break ionic crosslinks in the macromolecular matrix of a biofilm, facilitating the passage of solutes and surfactant through the matrix to bacteria entrained therein and/or protected thereby. Disruption of the macromolecular matrix advantageously also can result in detachment of the biofilm, alternatively or in addition to treating bacteria entrained in that matrix.
- The majority of the foregoing discussion has centered on biofilms, particularly bacterial biofilms. This is unsurprising given that a majority of sinus and otic issues have a bacterial origin. However, the composition exhibits efficacy against bacterial forms other than biofilms and against microbes other than bacteria. Advantageously, the composition can kill and/or prevent growth of microbes, regardless of their phase of life cycle.
- With respect to bacteria, each of the lag phase (metabolic protein production), log phase (reproduction) and stationary phase (approximately equal amounts of dying, metabolizing and reproducing bacteria) of a bacterium's lifecycle technically constitutes an “active” phase. Regardless of whether an individual bacterium is dormant, reproducing, or metabolizing, the composition can kill it or prevent it from growing.
- Bacteria that are part of biofilms often are dormant (not metabolizing or reproducing), and this lack of cellular processes (inactivity) often provides resistance to antibiotics, which require active metabolism or reproduction for efficacy, and other active antimicrobials.
- Viruses technically are not living microbes because they require a host for reproduction. Nevertheless, the composition is capable of disrupting, penetrating and/or dissolving the protein coating(s) on a virus. The ability to attack these protective structures means that the composition exhibits efficacy against a virus before it ever achieves the ability to reproduce after cellular infection.
- Ciliotoxicity generally increases with increasing surfactant concentration, increasing tonicity, and/or departure of pH from neutral. Given the foregoing description, the ordinarily skilled artisan can provide a ciliacompatible composition that remains effective against microbes in biofilm form.
- The composition can be employed in a variety of ways.
- For otic applications, it can be delivered to the targeted areas of the ear during and/or after surgery. This might be as simple as washing or rinsing the outer surface of a tympanic membrane, for example, one on which a surgical procedure is to be performed. (In such cases where the composition is not expected to pass the tympanic membrane, a composition with more aggressive pH and tonicity values can be employed.) For procedures involving access of the middle/inner ear, the composition can be delivered through a tympanostomy tube or via syringe inserted through a perforation or incision in the tympanic membrane. In both cases, a medical professional can continue to insert composition until liquid backflow is observed. (A typical human middle ear holds 1 to 1.5 mL of liquid, by way of example.)
- For sinus applications, the composition can be introduced to the sinus cavity via a surgical technique such as trephination or via a remote delivery mechanism such as, e.g., a Hydrodebrider™ endoscopic sinus irrigation system (Medtronic; Minneapolis, Minn.) or a Relieva Vortex™ sinus irrigation catheter (Acclarent, Inc.; Irvine, Calif.). Regardless of delivery mechanism, a medical profession can continue delivering composition to the targeted cavity(ies) until returning effluent appears visually clear.
- Regardless of where used, the composition can be permitted a dwell of time of a few seconds up to several hours. The targeted dwell time typically depends on the nature of the patient (e.g., ability to be sufficiently immobile to permit a long dwell time) as well as the physiology of the area to be treated, e.g., whether liquid introduced to that area naturally drains or pools.
- As mentioned previously, flushing or rinsing of the treated area typically is not necessary, although irrigation with a liquid such as a normal saline solution certainly is possible.
- The antimicrobial composition also or alternatively can be used to provide sterility to pre- and post-surgical articles such as sponges, topical wipes, bandages, pads, gauze, surgical packing, and the like, particularly those intended or expected to contact cilia-containing tissue.
- Although sterilized, medical device implants such as tympanostomy tubes can become colonized, prior to and during implantation, with bacteria from the environment, from a healthcare worker, or more commonly from bacteria present on the patient's own skin. After insertion, these implants can become colonized from systemic bacteria which make their way to the implant which provides a surface for biofilm growth because the implant surface is not protected by the host immune defenses. In addition, currently employed sterilization techniques are not designed to remove EPS/ECPS, the presence of which greatly facilitates formation of a biofilm; therefore, even a sterilized device/article that is properly implanted can have EPS/ECPS on its surface from previous exposure.
- If a biofilm forms on an implant, no currently available treatment can eradicate it. Systemic antibiotics are ineffective against such infections, certainly due to the inherent protection by the EPS/ECPS but also perhaps due to limited blood supply at the surface of the implanted article.
- The aforedescribed antimicrobial compositions can be effective topical treatments, applied to a to-be-implanted device or article or can be used to wash the infected implant and surrounding tissue to rid the body of a biofilm and/or biofilm-forming materials such as EPS/ECPS.
- The tympanic membrane where the implant is or was located likewise can be treated with the previously described composition. This can be done at the time of the original implantation (i.e., immediately following insertion of the article), and can be followed with rinsing/irrigation, suctioning or both.
- As has been mentioned several places above, deciliation is a significant concern for any composition that is intended for use in the sinus cavities and, particularly, the middle-inner ear. While deciliation is preferably avoided altogether, no more than ˜20%, preferably no more than ˜15%, and more preferably no more than ˜10%, is acceptable for compositions intended for use in sinus applications. For otic compositions, the acceptable upper limit is that which results in measurable hearing loss. Deciliation can be determined via scanning electron microscopy, as described more fully below, and/or audiometric testing.
- The relevant portions of any specifically referenced patent and/or published patent application are incorporated herein by reference.
- The relative efficacy of treating compositions was determined using a MBEC high throughput screening assay, similar to that used in the procedure described in ASTM E2799-12 (Standard Test Method for Testing Disinfectant Efficacy against Pseudomonas aeruginosa Biofilm Using the MBEC Assay). The assay employed a
multiwell assembly 10 of the type shown inFIG. 1 , which includesplate 12 havingmultiple wells 14 andlid 16 having multiple pegs 18. Each ofplate 12 andlid 16 is made of a plastic such as polystyrene or polycarbonate. - Bacteria is propagated in one or more of
multiple wells 14 immediately after aplate 12 is removed from sterile packaging. In the following examples, the plate included 96 wells in an array of 8 rows and 12 columns, as graphically represented inFIG. 2 . Each of 69 of the wells designated with an X received 150 μL of the 105 dilution inoculum. None of the wells in columns 9-11 were used, while wells A12-C12 were reserved for use as sterility controls. The five wells represented by D12-H12 served as bacterial growth controls. - The bacteria used were S. aureus, ATCC 33592 (MRSA), and P. aeruginosa, ATCC 15442. The surface of appropriate agar media were inoculated with a recently grown stock culture of each bacteria. An isolated colony was aseptically removed from the plate and inoculated with 200 mL of soybean-casein digest medium; flasks were incubated at 35°±2° C. and 150±10 rpm (18-24 hours for staph, 16-18 hours for pseudomonas) with viable bacterial densities being targeted at ≥108 CFU/mL, checked by serial dilution and plating. Into 100 mL portions of the growth medium were pipetted 10 μL aliquots from each incubation flask, so as to adjust the bacterial densities to 105 CFU/mL; these were vortexed to achieve homogeneous distributions. Ten-fold serial dilutions of the inoculums from the preceding sentence were performed in triplicate, with 20 μL aliquots of the serial dilutions being spot plated on appropriate agar plates from 100-10−7 before incubating the plates at 35°±2° C. (18-24 hours for staph, 16-18 hours for pseudomonas).
-
Lid 16 was placed onplate 12, andassembly 10 was labeled before being placed onto an orbital incubator/shaker set to 110±10 rpm. The incubator/shaker was allowed to run at 35°±2° C. for the amount of time noted previously as being appropriate for each bacterium type. - The bacterial growth pegs (D12-H12 in
FIG. 2 ) were broken off using flame sterilized pliers held flush againstlid 14. Each of those five pegs was placed into a separate sterile microcentrifuge tube with 1.0 mL phosphate-buffered saline (PBS). The microcentrifuge tubes then were placed on a stainless steel tray floated in the center of a sonication device; the tray was permitted to sonicate for 1800±300 seconds. After sonication, the solution in each microcentrifuge tube was serially diluted by transferring 0.1 mL into a new sterile microcentrifuge tube containing 0.9 mL PBS. The dilutions were spot plated onto agar appropriate for the particular bacterium being tested. - One plate, designated the “Challenge Plate,” is graphically depicted in
FIG. 3 , where the symbols represent the following: -
@ lysozyme-containing ★ PBS composition & 50:50 lysozyme-containing # lysozyme-free composition composition/sterile neutralizer {circumflex over ( )} saline * 50:50 lysozyme-free composition/ = sterile neutralizer sterile neutralizer ♦ sterile broth + 50:50 saline/sterile neutralizer - Into well A12 of that plate was added 200 μL sterile broth, with that well serving as the device sterility control. Next, 200 μL sterile neutralizer was added to each well in column 7 (neutralizer toxicity control) and well B12 (neutralizer sterility control), while the wells in column 6 (neutralizer effectiveness controls) received 100 μL sterile neutralizer followed by 100 μL of a test composition: lysozyme-containing composition in rows A-C, composition without lysozyme in rows D-F, and normal saline in rows G-H. To each well in column 8 (untreated control) and well C12 (PBS sterility control) was added 200 μL PBS. For columns 1-5, each well received 200 μL of a test composition: lysozyme-containing composition in rows A-C, composition without lysozyme in rows D-F, and normal saline in rows G-H.
- The Challenge Plate was placed into a humidified incubator set at 36°±1° C. for at least 60 minutes.
- Also provided for each test was a Rinse Plate (200 μL PBS in each well), a Recovery Plate (200 μL sterile neutralizer in each well), and Quantification Plates 1-3 (100 μL sterile neutralizer in row A of each and 180 μL PBS in rows B-H of each).
- The Challenge Plate was removed from the incubator. The Growth Plate peg lid was rinsed for ˜10 seconds to remove any planktonic microbes and transferred onto the Challenge Plate before the combination was incubated at 36°±1° C. for the appropriate time described above. Thereafter, the peg lid was transferred to the Recovery Plate.
- From the Challenge Plate was transferred 100 μL of the contents from each well of row A into the corresponding row A well of the
Quantification Plate Quantification Plate Quantification Plate 3. - The Recovery Plate was placed in the stainless steel tray of the sonicating device and permitted to sonicate for 1800±300 seconds.
- Dilution Plates 1-3 were prepared by adding 180 μL PBS into the wells of rows B-H of new 96-well multiwells. Following sonication, 100 μL of the contents from each well of row B of the Recovery Plate were transferred into the corresponding well of row A of
Dilution Plate 1. Serial dilutions (10° 40 were achieved by transferring 20 μL down each of the 8 rows, e.g., 20 μL from cell A1 was put into B1, diluted and mixed, 20 μL from cell B1 was put into C1, diluted and mixed, etc. The contents of each well ofDilution Plate 1 were mixed by pipetting up and down, with the pipette tip being discarded after mixing each row. The dilution series from theDilution Plate 1 was spot plated on appropriate agar for viable cell counts, described below. - Similarly, 100 μL of the contents from each well of row E of the Recovery Plate were transferred into row A of
Dilution Plate Dilution Plate 3. Dilution and spot plating for each were performed as withDilution Plate 1. - Each of Quantification Plates 1-3 were treated similarly to Dilution Plates 1-3.
- All agar plates were incubated at the appropriate temperature and for the appropriate time in view of the type of bacteria being tested.
- Each plate was visually inspected, with any colony that was visibly distinct from other colonies being counted as a colony forming unit (CFU) and that number being used in the following formula to determine relative efficacies of compositions at various concentrations:
-
log10[10x(CFU/V pl)(V w /A pg)] - where Vpl is the plated volume in μL, Vw is the volume of a plate well (here, 200 μL), Apg is the area of a lid peg (here, 46.63 mm2), and x is an integer representing the plate row, i.e., 1 for row A, 2 for row B, 3 for row C, etc. The average of the values for each of columns 1-5 were determined, and log reduction was determined by subtracting the average of treated pegs from the average of untreated pegs.
- As confirmations, pegs A12-C12 were checked to ensure that they remained clear, pegs D12-H12 were checked to ensure the presence of 104-106 CFU/mm2 of recovered microbe,
column 6 was checked to ensure neutralizer effectiveness,column 7 was checked to ensure neutralizer non-toxicity, andcolumn 8 was checked to ensure microbial growth. - Approximately 1 L of an exemplary solution for washing of the middle ear was prepared from the following combination of ingredients:
-
- 0.8 g/L anhydrous citric acid,
- 19.1 g/L trisodium citrate dihydrate,
- 50 g/L ethanol, and
- 0.15 g/L lysozyme.
The composition was calculated to have an effective solute concentration of ˜200 mOsm/L, and its measured pH was 6.5.
- When tested in a MBEC biofilm reactor, with a 5 minute static application time, this composition was shown to result in a 0.8 log reduction in S. aureus and a 2.2 log reduction in P. aeruginosa.
- Approximately 1 L of an exemplary solution for introduction into the sinuses was prepared from the following combination of ingredients:
-
- 0.75 g/L anhydrous citric acid,
- 14.25 g/L trisodium citrate dihydrate,
- 100 g/L DMSO,
- 0.15 g/L lysozyme, and
- 5 g/L sodium lauryl sulfate.
The composition was calculated to have an effective solute concentration of ˜200 mOsm/L, and its measured pH was 7.0.
- When tested in a MBEC biofilm reactor, with a 5 minute static application time, this composition reduced S. aureus by 3 log.
- The ALI model, which uses epithelial tissue grown on permeable filter supports submerged in culture medium, was used as a screening test to determine whether the composition employed in Example 2 exhibited significant ciliotoxicity.
- Mucosal specimens acquired from residual clinical material obtained during sinonasal surgery were transported to the laboratory in saline placed on ice. ALI cultures were established from human sinonasal epithelial cells enzymatically dissociated human tissue using procedures described at, for example, M. Ramanathan et al., “A comparison of experimental methods in molecular chronic rhinosinusitis research.” Am. J. Rhinol., vol. 21, pp. 373-77 (2007).
- Cultures were grown to confluence in tissue culture flasks (75 mL) with an appropriate proliferation medium before the epithelium was allowed to differentiate five days later.
- Mucosal samples prepared according to the procedure described in M. B. Antunes et al., “Murine Nasal Septa for Respiratory Epithelial Air-Liquid Interface Cultures,” BioTechniques, no. 43, pp. 195-204 (2007) were placed in a glass perfusion chamber.
- Beating cilia on the edges of each sample were identified using a Leica DMLFSA microscope set on an air table, using a water immersion 63×objective and differential inter-ference contrast optics (Leica Microsystems, Inc.; Bannockburn, Ill.). Once beating cilia were observed, two seconds of video at a sampling rate of 100 frames/second were captured with a high-speed monochromatic digital video camera (Basler AG; Ahrensburg, Germany), with the video images being routed into a PC workstation for compression and storage. This process was repeated at 1-minute intervals, with a 5-minute baseline beating rate being determined before 20 μL of the composition from Example 2 was pipetted onto the apical surface of the mucosal sample and video imaging was continued. Image files were analyzed with virtual instrumenta-tion software customized to analyze ciliary beating. (For more information on this type of video image analysis technique, see J. H. Sisson et al., “All-digital image capture and whole-field analysis of ciliary beat frequency,” J. Microscopy, vol. 211, pp. 103-11 (2003).)
- The targeted result was a finding that at least 50% of cilia (as measured by active area) would continue beating through 30 minutes of exposure of a sample to the composition.
- The actual results of the testing are shown in
FIG. 4 . The median active area for the baseline period was ˜24.3%, while the median active area as measured at 30-33 minutes was ˜16.4%. Accordingly, the treating composition from Example 2 was deemed to have passed the ALI screening test. - The beat frequency of the cilia during exposure to the treating composition from Example 2 also was measured, with those results being shown in
FIG. 5 . The median cilia beat frequency for the baseline testing was ˜4670 Hz, while the median for the solution at 30-33 minutes of exposure was ˜3160 Hz.FIG. 5 also indicates that cilia beat frequency continues to increase after exposure. - The sinus treating composition from Example 2 also was tested on three harvested mouse nasal septa. (Harvesting was conducted as described in the M. B. Antunes et al. article mentioned previously.)
- Each harvested septal explant was held in sterile PBS before being placed in a glass perfusion chamber held in place with a nylon grid (1.5 mm), the outer frame of which snapped into the inside of the perfusion chamber (Warner Instruments; Hamden, Conn.). Each explant was tested at 27.5° to 28.5° C.
- A 3-minute baseline beating rate was determined before each explant sample was given a 3-minute exposure to the sinus treating composition from Example 2.
- The video image analysis technique employed in Example 3 again was employed.
- Tabulated below are the median cilia beat frequency for the baseline period and 27-30 minutes after exposure.
-
TABLE 2 cilia beat frequency of mouse explants (Hz) Baseline Post-exposure sample 1 4.8 8.0 sample 25.1 6.1 sample 36.6 8.9 - The cilia beat frequency values after exposure are greater than those before exposure, indicating no debilitating damage to the cilia of the explant samples.
- The sinus treating composition from Example 2 also was tested on ciliated mucosal surfaces in the sinuses of living rabbits at the University of Sao Paolo.
- Using the procedure described in E, Tamashiro et al., “In vivo effects of citric acid/zwitterionic surfactant cleansing solution on rabbit sinus mucosa,” Am. J. of Rhinology & Allergy, vol. 23, no. 6, pp. 597-601 (2009), indwelling catheters were placed into the maxillary sinuses of female New Zealand white rabbits, with 10 mL (at a rate of 0.33 mL/sec) of either 0.9% normal saline or the treating composition from Example 2 being instilled into the sinuses, followed by aspiration.
- Test rabbits were anaesthetized and killed either one day or seven days after irrigation. The 7-day timeframe permits evaluation of possible long-term deciliation, while the 1-day timeframe guards against the possibility of immediate deciliation followed by regrowth in the intervening six days. (Sinus cilia often regrow within 48 hours of being lost.)
- Mucosa from both left and right maxillary sinuses were harvested, with each mucosa sample being evaluated by scanning electron microscopy (SEM) for morphological integrity of the epithelium.
- Analysis of the SEM images indicated the ciliotoxicity of the treating composition from Example 2 equivalent to or even less than that of normal saline, both after 1 day and after 7 days.
- Ototoxicity testing was conducted by the Department of Otolaryngology in the University of Florida College of Medicine, employing internally approved animal handling/testing procedures which conform to the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
- After an acclimation period of at least 5 days, each of eight mature, albino male guinea pigs (Charles River; Wilmington, Mass.) underwent a bilateral myringotomy, conducted with a blunt 27 gauge sterile needle. Sufficient liquid was injected so as to fill the animals' middle ear spaces (˜0.2 mL), with one ear receiving a control 0.9% normal saline solution and the other receiving the treating composition from Example 1. After injection, the dorsal skull of each animal was tapped gently to ensure thorough exposure of the entireties of the animal's middle and inner ears to the liquids.
- None of the test animals displayed evidence of vestibulopathy during the study.
- Cochlear action potential for each animal was measured before solution injections, 7 days after injection, and 28 days after injection, using electrocochleography as described by T. M. Lo et al., “Hearing loss with stapedotomy and treated otitis media,” Otolayngol. Head Neck Surg., vol. 134(4), pp. 674-79 (April 2006). Electrocochleographic thresholds were measured for calibrated tone bursts generated by an auditory electrophysiology workstation using software from Tucker-Davis Technologies (Gainesville, Fla.) and electrostatic speakers. Stimuli were introduced through insert headphones placed in the animal's external auditory canal. Tone bursts at frequencies of 4 kHz, 8 kHz, 16 kHz and 24 kHz were presented. Beginning at 100 dB, auditory thresholds were evaluated by decreasing stimulus intensity in 5 dB decrements until disappearance of the waveform. Waveforms were averaged in response to 512 tone bursts at each tested frequency/amplitude combination.
- Hearing thresholds for each ear were compared using a paired, two-tailed t-test (SAS Institute Inc.; Cary, N.C.). Significance levels were determined at p<0.05.
- A significant hearing loss for these experiments was considered to be a 10 dB difference.
- Averaged hearing thresholds for the test animals prior to injection of any liquids can be seen in
FIG. 6 , while averaged hearing threshold shifts for thetest animals 7 days and 28 days after liquid injection can be seen in, respectively,FIGS. 7 and 8 . (Bars represent standard error.) - In each case, hearing thresholds between treatments were not different at all frequencies (p>0.05).
- After final hearing assessments, each animal was euthanized so that their cochlea could be examined by SEM so as to assess outer hair cell (OHC) loss. When possible the cochlea were imaged from all three turns, i.e., basal, middle and apical.
- Thorough analysis of multiple images revealed no substantial difference in the OHC loss of the middle ears receiving the treating composition from Example 1 relative to the ears receiving the control saline solution.
- Based on both the comparative hearing data and the SEM analysis, the report concluded that the treating composition employed in Example 1 did not cause ototoxicity. The results were deemed to be sufficiently definitive that a follow-on confirmative study employing chinchillas was recommended to be foregone.
Claims (20)
1. A method for treating a cilia-containing area of an animal body, said method comprising:
a) introducing to said area a composition having a pH of from 6 to 8 and an effective solute concentration of no more than 400 mOsm/L, wherein said composition consists of
(1) a solvent component that comprises water and at least 2% (w/v) of one or more organic liquids, and
(2) a solute component that comprises organic acid, no more than 1% (w/v) anionic surfactant, and at least 0.005% (w/v) of one or more enzymes which are active at 6≤pH≤8; and
b) permitting said composition to lyse bacteria contained in said area.
2. The method of claim 1 wherein said composition has an effective solute concentration of no more than 250 mOsm/L.
3. The method of claim 1 wherein said composition has an effective solute concentration of no more than 200 mOsm/L.
4. The method of claim 1 wherein said organic acid is a polyacid.
5. The method of claim 4 wherein said polyacid is citric acid.
6. The method of claim 1 wherein said solute component further comprises a buffer precursor.
7. The method of claim 6 wherein said buffer precursor comprises a salt of said organic acid.
8. The method of claim 7 wherein said salt of an acid is a sodium salt of citric acid.
9. The method of claim 1 wherein said solute component comprises no more than 0.8% (w/v) anionic surfactant.
10. The method of claim 9 wherein said solute component comprises no more than 0.7% (w/v) anionic surfactant.
11. The method of claim 10 wherein said solute component comprises no more than 0.5% (w/v) anionic surfactant.
12. The method of claim 1 wherein said cilia-containing area is a sinus cavity.
13. The method of claim 1 wherein said solute component is free of anionic surfactant.
14. The method of claim 13 wherein said cilia-containing area is the middle or inner ear.
15. The method of claim 1 wherein said one or more enzymes is lysozyme.
16. The method of claim 1 wherein said one or more organic liquids comprises DMSO.
17. The method of claim 1 wherein said one or more organic liquids comprises ethanol.
18. A process for treating a sinus cavity of an animal, said method comprising:
a) introducing to said sinus cavity a composition having a pH of from 6 to 8 and an effective solute concentration of from 100 to 275 mOsm/L, wherein said composition consists of
(1) a solvent component that comprises water and from 2 to 20% (w/v) DMSO, and
(2) a solute component that comprises 0.1 to 50 g/L organic acid, from 10 to 65 g/L anionic surfactant, from 60 to 400 ppm of one or more enzymes which are active at 6≤pH≤8, and a buffer precursor; and
b) permitting said composition to lyse bacteria contained in said sinus cavity.
19. A method for treating the middle or inner ear of an animal, said method comprising:
a) introducing to the ear cavity of said animal a composition having a pH of from 6 to 8 and an effective solute concentration of from 100 to 275 mOsm/L, wherein said composition consists of
(1) a solvent component that comprises water and from 2 to 9% (w/v) ethanol, and
(2) a solute component that comprises 0.1 to 50 g/L organic acid, less than 0.5 g/L anionic surfactant, from 60 to 400 ppm of one or more enzymes which are active at 6≤pH≤8, and a buffer precursor; and
b) permitting said composition to lyse bacteria contained in said ear cavity.
20. The method of claim 19 wherein said one or more enzymes is lysozyme.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/402,535 US20210368788A1 (en) | 2016-06-30 | 2021-08-14 | Methods for using antimicrobial compositions |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662357147P | 2016-06-30 | 2016-06-30 | |
US201762524522P | 2017-06-24 | 2017-06-24 | |
PCT/US2017/039836 WO2018005702A1 (en) | 2016-06-30 | 2017-06-28 | Antimicrobial compositions and methods employing same |
US201816314168A | 2018-12-28 | 2018-12-28 | |
US17/402,535 US20210368788A1 (en) | 2016-06-30 | 2021-08-14 | Methods for using antimicrobial compositions |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/314,168 Continuation US11090369B2 (en) | 2016-06-30 | 2017-06-28 | Antimicrobial compositions and methods employing same |
PCT/US2017/039836 Continuation WO2018005702A1 (en) | 2016-06-30 | 2017-06-28 | Antimicrobial compositions and methods employing same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210368788A1 true US20210368788A1 (en) | 2021-12-02 |
Family
ID=59399472
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/314,168 Active 2038-03-14 US11090369B2 (en) | 2016-06-30 | 2017-06-28 | Antimicrobial compositions and methods employing same |
US17/402,535 Pending US20210368788A1 (en) | 2016-06-30 | 2021-08-14 | Methods for using antimicrobial compositions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/314,168 Active 2038-03-14 US11090369B2 (en) | 2016-06-30 | 2017-06-28 | Antimicrobial compositions and methods employing same |
Country Status (8)
Country | Link |
---|---|
US (2) | US11090369B2 (en) |
EP (1) | EP3478066A1 (en) |
JP (1) | JP2019521121A (en) |
CN (1) | CN109310087A (en) |
AU (1) | AU2017290082A1 (en) |
BR (1) | BR112018077060A2 (en) |
CA (1) | CA3029601A1 (en) |
WO (1) | WO2018005702A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11672773B2 (en) | 2020-12-13 | 2023-06-13 | Next Science IP Holdings Pty Ltd | Methods for treating ciliated cavities |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9872843B2 (en) | 2011-10-08 | 2018-01-23 | Next Science, Llc | Antimicrobial compositions and methods employing same |
JP6430490B2 (en) | 2013-05-02 | 2018-11-28 | ネクスト サイエンス アイピー ホールディングス ピーティワイ エルティーディ | Highly permeable antimicrobial composition comprising one or more organic solvents |
AU2018367660A1 (en) | 2017-11-19 | 2020-06-11 | Next Science IP Holdings Pty Ltd | Compositions and methods for treating intervertebral discs |
CA3198601A1 (en) * | 2020-10-14 | 2022-04-21 | Next Science IP Holdings Pty Ltd | Hard surface disinfecting composition |
CN113391061A (en) * | 2021-06-16 | 2021-09-14 | 王婷楠 | Application of animal immune antibody in preparation of medicine for detecting animal immunity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007134055A1 (en) * | 2006-05-10 | 2007-11-22 | Medtronic Xomed, Inc. | Antibacterial extracellular polysaccharide solvating system |
WO2008070387A1 (en) * | 2006-12-01 | 2008-06-12 | Laclede, Inc. | Use of hydrolytic and oxidative enzymes to dissolve biofilm in ears |
WO2010011605A2 (en) * | 2008-07-21 | 2010-01-28 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5041236A (en) * | 1989-10-27 | 1991-08-20 | The Procter & Gamble Company | Antimicrobial methods and compositions employing certain lysozymes and endoglycosidases |
FR2750865B1 (en) * | 1996-06-27 | 1998-12-04 | Rhone Merieux | RECOMBINANT LIVING VACCINE BASED ON CANINE HERPESVIRUS, IN PARTICULAR FOR SQUARE DISEASE, RABIES OR TYPE 2 PARAINFLUENZA VIRUS |
US20020022005A1 (en) * | 1997-10-16 | 2002-02-21 | Budny John A. | Compositions for treating cystic fibrosis |
US6159447A (en) * | 1997-10-16 | 2000-12-12 | Pharmacal Biotechnologies, Llc | Compositions for controlling bacterial colonization |
US6610314B2 (en) | 2001-03-12 | 2003-08-26 | Kimberly-Clark Worldwide, Inc. | Antimicrobial formulations |
CN100450546C (en) * | 2002-01-28 | 2009-01-14 | 上海高科生物工程有限公司 | Compound preparation for dissolving staphyloase and preparation method |
US7090882B2 (en) | 2003-06-12 | 2006-08-15 | Cargill, Incorporated | Antimicrobial salt solutions for food safety applications |
CN1315532C (en) * | 2004-10-19 | 2007-05-16 | 上海新药研究开发中心 | Compound lysoamidase spray agent and preparing method |
US20070264296A1 (en) | 2006-05-10 | 2007-11-15 | Myntti Matthew F | Biofilm extracellular polysachharide solvating system |
US7993675B2 (en) * | 2006-05-10 | 2011-08-09 | Medtronic Xomed, Inc. | Solvating system and sealant for medical use in the sinuses and nasal passages |
US7959943B2 (en) * | 2006-05-10 | 2011-06-14 | Medtronics Xomed, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
WO2009152374A2 (en) * | 2008-06-12 | 2009-12-17 | Medtronic Xomed, Inc. | Method for treating chronic wounds |
EP2346324A4 (en) | 2008-10-06 | 2012-10-10 | Microbial Defense Systems Llc | Antimicrobial composition and methods of making and using same |
US9872843B2 (en) | 2011-10-08 | 2018-01-23 | Next Science, Llc | Antimicrobial compositions and methods employing same |
JP6430490B2 (en) | 2013-05-02 | 2018-11-28 | ネクスト サイエンス アイピー ホールディングス ピーティワイ エルティーディ | Highly permeable antimicrobial composition comprising one or more organic solvents |
CN107899006A (en) * | 2017-11-28 | 2018-04-13 | 四川清舒乐科技有限公司 | Pharmaceutical composition of nasal irrigation and preparation method thereof |
-
2017
- 2017-06-28 US US16/314,168 patent/US11090369B2/en active Active
- 2017-06-28 AU AU2017290082A patent/AU2017290082A1/en not_active Abandoned
- 2017-06-28 CN CN201780037042.4A patent/CN109310087A/en active Pending
- 2017-06-28 JP JP2018567613A patent/JP2019521121A/en active Pending
- 2017-06-28 WO PCT/US2017/039836 patent/WO2018005702A1/en unknown
- 2017-06-28 EP EP17743416.4A patent/EP3478066A1/en not_active Withdrawn
- 2017-06-28 CA CA3029601A patent/CA3029601A1/en not_active Abandoned
- 2017-06-28 BR BR112018077060-4A patent/BR112018077060A2/en not_active IP Right Cessation
-
2021
- 2021-08-14 US US17/402,535 patent/US20210368788A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007134055A1 (en) * | 2006-05-10 | 2007-11-22 | Medtronic Xomed, Inc. | Antibacterial extracellular polysaccharide solvating system |
WO2008070387A1 (en) * | 2006-12-01 | 2008-06-12 | Laclede, Inc. | Use of hydrolytic and oxidative enzymes to dissolve biofilm in ears |
WO2010011605A2 (en) * | 2008-07-21 | 2010-01-28 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11672773B2 (en) | 2020-12-13 | 2023-06-13 | Next Science IP Holdings Pty Ltd | Methods for treating ciliated cavities |
Also Published As
Publication number | Publication date |
---|---|
AU2017290082A1 (en) | 2018-12-13 |
JP2019521121A (en) | 2019-07-25 |
WO2018005702A1 (en) | 2018-01-04 |
US11090369B2 (en) | 2021-08-17 |
CA3029601A1 (en) | 2018-01-04 |
BR112018077060A2 (en) | 2019-04-24 |
US20190262433A1 (en) | 2019-08-29 |
CN109310087A (en) | 2019-02-05 |
EP3478066A1 (en) | 2019-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210368788A1 (en) | Methods for using antimicrobial compositions | |
AU2022200778B2 (en) | High osmolarity antimicrobial composition containing one or more organic solvents | |
US8940792B2 (en) | Antimicrobial composition and methods for using same | |
CN101443079A (en) | Antibacterial extracellular polysaccharide solvating system | |
MX2007015855A (en) | Compositions and methods of use. | |
JP2018524999A (en) | Antibacterial composition having efficacy against endospores | |
US8557265B2 (en) | Use of a synergistic composition as a therapeutic agent of disinfectant | |
US11672773B2 (en) | Methods for treating ciliated cavities | |
KR20190022542A (en) | A composition comprising at least one enzyme and at least one antiseptic molecule for the prevention or treatment of infection after transplantation | |
JP2012524570A (en) | Method for killing mycobacteria or inhibiting its growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |